



AAI

THE AMERICAN
ASSOCIATION OF
IMMUNOLOGISTS

NEWSLETTER

JULY 2023



2023 AAI Election Results

PAGE 8



THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS
1451 Rockville Pike, Suite 650, Rockville, MD 20852



Multispecific Antibody Development Solutions

From Lead Discovery to Process Development and Clinical Studies

Highly Efficient Platforms for Developing Antibodies with a High Success Rate

Multiple Technology Platforms

- Phage-display, single B cell discovery (Beacon® and FACS), and hybridoma development platforms

Covering the Entire Development Process

- From antigen design and preparation to animal immunization, through to the antibody production

Highly Experienced Antigen Design and R&D Team

A Large Collection of Quality Target Proteins

- CD3 proteins, multi-pass transmembrane proteins, immune checkpoint target proteins, and more


Recombinant Antigen Production Services

- Diverse systems: mammalian cells, insect cells, *E. coli*, and HEK293/CHO stable cell lines



Learn more about our solutions for multispecific antibody!

Learn More



Excellent Antibody Humanization and Affinity Maturation Platforms

Antibody Humanization Service

- 100% success rate
- Fast delivery: 3-4 weeks
- Affinity validated by ELISA/SPR/BLI

AI-Powered Affinity Maturation Service

- Lead time: 4 weeks
- Affinity can be increased 10^3 times
- Screen up to 10^{10} sequence space

Well-established Antibody Drug Evaluation System

Professional and Standardized

- ISO 9001 & CNAS certified, robust quality management system

One-stop Solutions

- Comprehensive services and reagents, multi-dimensional efficacy evaluation system

www.sinobiological.com



Sino Biological US Inc. (U.S.A.)

Tel: +1-215-583-7898

Email: cro_us@sinobiologicalus.com

Sino Biological Europe GmbH (Europe)

Tel: +49(0)6196 9678656

Email: cro-service@sinobiological.com

Sino Biological, Inc. (Global)

Tel: +86-400-890-9989

Email: cro-service@sinobiological.com

株式会社日本シノバイオロジカル (Japan)

Tel: 044-400-1330

Email: cro-service@sinobiological.co.jp



The American Association of Immunologists

1451 Rockville Pike, Suite 650
Rockville, MD 20852
Tel: 301-634-7178
Fax: 301-634-7887
Email: infoaai@aai.org
www.aai.org

Member Services

Tel: 301-634-7195
Email: members@aai.org

The Journal of Immunology
and
ImmunoHorizons
Tel: 301-634-7197
Email: infoji@aai.org
www.jimmunol.org
www.immunohorizons.org

Council

President

Akiko Iwasaki, Ph.D.

Vice President

Stephen Jameson, Ph.D.

Past President

Mark M. Davis, Ph.D.

Secretary-Treasurer

Joan Goverman, Ph.D., DFAAI

Councilors

Ulrich H. von Andrian, M.D.
Avery August, Ph.D.
Susan M. Kaech, Ph.D.
Maria-Luisa Alegre, M.D., Ph.D., DFAAI

Ex Officio Members

Loretta L. Doan, Ph.D.,
AAI Chief Executive Officer
Daniel J. Campbell, Ph.D.
Cathryn R. Nagler, Ph.D., DFAAI
Eugene M. Oltz, Ph.D., DFAAI

To see a list of AAI staff, visit
www.aai.org/staff

© The American Association of Immunologists, Inc.



- 4 Executive Office
- 11 Public Affairs
- 17 Members in the News
- 20 In Memoriam
- 22 Awards
- 27 Outreach
- 30 Publications
- 31 Feature: Lessons from the Annual Meeting Roundtables
- 33 History
- 38 Grants and Awards Deadlines
- 41 Meetings and Events



About the Cover: The cover image featuring Hope E. Hopps never identified her by name until 2018. Known in captions only as “female lab technician,” she was an experienced bacteriologist who contributed greatly to the work of the Laboratory of Viral Immunology. Read more on page 35.



4 President's Message from Akiko Iwasaki



10 AAI Campaign Wins Gold Circle Awards





30 Bishop Appointed New *Jl* Editor-in-Chief

Connect with AAI!

Do you have a story or story idea for a future issue of the *AAI Newsletter*? Wish to receive AAI alerts? Send us an email! Interested in the latest news from AAI? Keep in touch through our social media channels. Follow us on social media and keep abreast of daily developments in the world of immunology.


 @ImmunologyAAI


 @J_Immunol
(*The Journal of Immunology*)

 @ImmunoHorizons
(*ImmunoHorizons*)

 @ImmunologyAAI

 [linkedin.com/company/the-american-association-of-immunologists](https://www.linkedin.com/company/the-american-association-of-immunologists)

 AAINewsletter@aai.org
(story ideas and comments about the *AAI Newsletter*)

 @ImmunologyAAI

 @AAIImmunology

AAI President's Message



Akiko Iwasaki, Ph.D., AAI '00
Sterling Professor of Immunobiology and Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology (Microbial Diseases); Director, Center for Infection and Immunity
Yale School of Medicine

Investigator, Howard Hughes Medical Institute

It is with great honor and delight that I accept the role of president of the American Association of Immunologists. Over the past five years, I have had the pleasure of working with the AAI Council and have gained valuable insights into how this organization tirelessly serves its members. The various activities and services of AAI do not happen by chance but are a result of the hard work and dedication of the previous and current presidents, vice presidents, Council members, and committee members, as well as the incredible staff that supports AAI.

I have fond memories of my time thus far as an AAI Council member. I was always in awe of the presidents, all brilliant scientists and leaders in the field of immunology who also tirelessly served AAI. They have included then-president JoAnne Flynn (2018–2019) and her successors. JoAnne was incredibly kind and generous with her time in showing me the ropes and giving me the confidence I needed as a first-year Council member. Jeremy Boss (2019–2020) showed great resilience by adapting and pivoting from the original 2020 annual meeting plans to deal with the emerging pandemic. Jenny Ting (2020–2021) paved the way as the first woman of color to lead AAI and served with such grace and conviction. Gary Koretzky (2021–2022), with his infinite wisdom and finesse, brought about important changes to the organization and tirelessly worked on behalf of AAI. Mark Davis (2022–2023) brought increased focus on human immunology and cutting-edge technologies and introduced a more relaxed atmosphere to Council meetings. I have the privilege of watching how the wheels turn behind the scenes at AAI and am in awe of the incredible dedication of all who have served on its Council and committees over the years. It is daunting to follow the acts of these great leaders, but I am truly inspired by their examples to serve in this important role.

While the immune system is essential to the survival of every living organism and has a wide-ranging impact on health and disease, the field of immunology was thrust into the spotlight

during the COVID-19 pandemic. Immunologists worked tirelessly, and there have been remarkable accomplishments made, including the speedy development and deployment of effective vaccines, rapid dissemination of viral testing, and approvals of various therapeutic modalities. At the same time, we continue to face many obstacles to controlling the viral spread, with the emergence of new variants of concern that caused wave after wave of infections throughout the world.

Some sequelae of COVID-19 include pulmonary embolism, cardiac arrest, heart failure, death, stroke, and diabetes, to name a few. These sequelae turned the notion of “acute respiratory infection” on its head, as nothing about these outcomes is acute or confined to the respiratory tract. In addition to acute COVID, roughly 10 percent of the infected develop long COVID. This can be a debilitating condition that involves more than 200 symptoms, most commonly fatigue, post-exertional malaise, cognitive dysfunction, tachycardia, loss or altered smell and taste, and many others.

COVID is not alone in causing chronic conditions following acute infection. A cluster of diseases collectively known as post-acute infection syndrome (PAIS) can follow infection with a dozen other infectious agents, including viruses, bacteria, and parasites, and can lead to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Collectively, PAIS is a complex disorder with a poorly understood pathogenesis. To develop effective therapies, it is essential that patients, researchers, and clinicians work together to pool their knowledge and expertise.

From this pandemic, we have also learned much about what we know and don't yet know in terms of basic immunology. We still have yet to figure out how to make a vaccine that develops long-lasting cross-protective immunity, and how to improve future vaccines so that they not only prevent diseases but also infection and transmission. We also do not yet have a correlate of protection at the mucosal surfaces. To this end, it is encouraging to see the recent White House initiative Project NextGen, which has invested \$5 billion towards creating long-lasting cross-protective monoclonal antibodies and vaccines. This will speed the development of mucosal vaccines to possibly reduce transmission and infection risks and speed efforts to develop a universal coronavirus vaccine that protects against COVID-19 and other coronaviruses.

Infectious diseases are but one of the many challenges and opportunities for us as immunologists. Recent years have brought deeper insights into the role of the immune system in a large number of disease areas not historically

considered immune diseases. It appears that the immune system is responsible for the pathogenesis of wide-ranging diseases—an insight that offers many possibilities in terms of immunotherapies. Many fundamental questions remain to be answered about the potential immunological underpinnings of cancer; aging; and many diseases, including neurodegenerative, cardiovascular, psychiatric, and metabolic. These diseases present challenges but also opportunities for immunologists to advance our knowledge and make a real difference in the lives and well-being of people around the world.

The future of immunology offers so much to be excited about. There is rapid development and refinement of new tools that enable us to do many types of analyses and manipulations of genome, transcriptome, epigenome, proteome, metabolome, and cells and tissues. Artificial intelligence now enables predictive modeling, design automation, and high-throughput screening, which can transform protein engineering and drug discovery. These new technologies, when applied to the right questions with the right approach, can bring about new insights and treatments at an unprecedented speed. At the same time, having access to these powerful and plentiful tools makes it all too easy to fall into randomly trying many omics approaches without a clear direction, which could lead to a plethora of big data without necessarily offering much insight. Now more than ever, graduate and postdoctoral education must incorporate critical and scientific thinking at the forefront.

Turning inward to focus on AAI, we must ask, what can AAI do for its members? In close collaboration with the new CEO, Dr. Loretta Doan, and the AAI leadership, I hope to contribute to key changes that can further improve this already amazing organization. First and foremost, I would like to help revamp AAI to serve the next generation of immunologists from diverse backgrounds. Young scientists are the future of immunology, and what better way to spend our efforts and resources than to focus on these future scientists? To this end, we are already seeing concrete improvements. In 2023, we started providing on-site childcare free to our members so mothers and fathers can attend the meeting and still enjoy being with their children at the venue. AAI also ended the practice of holding the annual meeting over Mother's Day weekend—starting with 2024, annual meetings will be held on April or May non-holiday weekends. AAI is also committed to hosting meetings in states that protect women's reproductive rights. I am excited that the 2024 annual meeting will take place in Chicago!

I want to take this opportunity to highlight some of the member-serving efforts that are ongoing at AAI, which include awards, courses, publications, annual meetings, and public policy. One office I wish to highlight is the Public Policy and Government Affairs office, headed by Lauren Gross, J.D. Lauren, together with Jake Schumacher and Emily Kansler, Ph.D., provides an incredible wealth of knowledge on the up-to-date happenings on the Hill and guides the Council on how to navigate impending changes in Congress or the Department of Health and Human Services with the

potential to impact the direction of federal research and funding. This office also supports the Public Policy Fellows program, which has produced 118 Fellows (with an additional 10 who just started their fellowship year) who are making important public policy contributions. AAI also has a History and Archives office that offers a wealth of information about its history, members, and the field of immunology's contributions to the world, capably run by John Emrich, Ph.D.

Every year, AAI provides \$2.5 million in funding for young investigators in the form of fellowship programs and awards. The AAI Career Development and Awards office headed by Mary Litzinger, Ph.D., ensures that these awards are given to the top deserving candidates every year. These include the Careers in Immunology Fellowship Program, Intersect Fellowship Program, Career Reentry Fellowship Program, and Travel for Techniques Program. We also offer the Grant Review for Immunologists Program, which benefits early career investigators. The ASPIRE Awards for Early Career Investigators were created last year to recognize and encourage young immunologists with great promise. AAI also recognizes the contributions of more established immunologists through many awards, including the Lifetime Achievement Award, Distinguished Service Award, Distinguished Fellows of AAI, Public Service Award, Vanguard Award, Excellence in Mentoring Award, Steinman Award for Human Immunology Research, BioLegend Herzenberg Award, Thermo Fisher Meritorious Career Award, BD Biosciences Investigator Award, and the new Lancefield Mid-Career Achievement Award.

Another critical mission of AAI is to educate. To this end, AAI offers annual courses in both introductory and advanced immunology, taught by leaders in the field. These courses are always in high demand and regularly filled to capacity. AAI also conducts outreach programs, including the High School Teachers Summer Research Program in Immunology, offering high school science teachers an opportunity to learn more about immunology and assistance in developing a curriculum that can be used to pass this knowledge on to their students.

The annual AAI meetings are our scientific and social highlight of the year. They bring together an average of 3,200 immunologists every year from around the world, about 72 percent of whom represent AAI members. The annual meetings are not only great venues to learn about cutting-edge immunology, but also a place to meet fellow immunologists face to face and to make new connections and collaborations. These meetings require a huge amount of coordination years in advance, which is handled by the capable Meetings office headed by Gale Guerrieri.

The Membership office, headed by Jenny Woods, handles all aspects of establishing and sustaining scientists' and trainees' AAI membership and ensuring the delivery of membership benefits. Even though AAI is an American association in name, one of our goals is to increase both domestic and international membership, because international and interdisciplinary collaboration is essential to the success of immunology.

The Journal of Immunology (*The JI*), AAI's flagship member journal, and its sister journal, *ImmunoHorizons*, have served as important journals in the field of immunology and are managed by the Editorial Office, led by Catherine Wattenberg. Dr. Eugene M. Oltz has been a dedicated and tireless editor-in-chief of *The JI* for five years. His vision and expertise have helped to make *The JI* one of the most respected and influential journals in the field of immunology. We are all grateful for his service and for his contributions to the field. AAI is pleased to welcome Dr. Gail Bishop as the new *Ji* editor-in-chief. Dr. Bishop is a leader in the field of immunology and a former AAI president (2012–2013), and we are confident that she will continue to build on *The JI*'s reputation as a leading journal in the field. *ImmunoHorizons* is a fully open-access, peer-reviewed, online-only journal committed to advancing the knowledge of immunology. We are fortunate to have Dr. Mark Kaplan serving as the editor-in-chief (he is easy to spot at the AAI annual meetings—just look for a green T-shirt or green sunglasses!). These journals have also been the major income source for our association. With the requirements to meet the open-access policy, we need to develop creative ways to raise funds and maintain the quality of service to our membership. This will be one of our key goals for Dr. Doan and the AAI leadership.

AAI is already serving its members in so many ways, but this is just the beginning! The best way to learn about the needs of its members is to ask! We will be asking how AAI can better serve

you. We want to bring the maximum value to our membership that nurtures and supports the careers of future and current immunologists.

Turning our focus outward, what can AAI do for the world? As scientists, we are heavily supported by taxpayers, and as such, we owe the public clear communication about science and the scientific research we have the privilege of conducting. Beyond our own science, the importance of science communication has never been more in demand than during the pandemic and will become ever more important in the future. I am thrilled to continue the AAI public awareness campaign efforts launched by then-president Gary Koretzky. With the competent leadership and experience of the AAI Communications office, directed by Bethany Coulter, I am looking forward to continuing the work of making AAI the go-to resource for media and the public regarding information related to immunology in health and disease. We want AAI to be THE resource people go to when they google “the immune system,” “how vaccines work,” “allergy,” “immunotherapy,”—and likewise when a reporter needs to speak to an expert about a new vaccine or a therapy for cancer. We are also working steadily to widen our reach to younger audiences through social media engagement.

I hope that you will join me in making AAI a great resource for its members, those in the general public and media, and others around the world!

PRESIDENT'S PROFILE: AKIKO IWASAKI, PH.D. (AAI '00)

Akiko Iwasaki, a member of the AAI Council since her election in 2018, commenced her leadership of AAI as the 107th president on July 1.

Dr. Iwasaki is a Howard Hughes Medical Institute (HHMI) investigator; Sterling Professor of Immunobiology; Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology (Microbial Diseases); and Director of the Center for Infection and Immunity at Yale School of Medicine.

Iwasaki has made significant contributions to the field of immunology. Her groundbreaking research has shed light on the recognition of viral genomic material by Toll-like receptors, the role of innate immune responses in viral infections such as rhinovirus and Zika virus, and the establishment of tissue-resident memory T cells and B cells through innovative vaccine strategies. A primary aspect of her current research focuses on the mechanisms of immune defense against viruses at the mucosal surfaces and the development of mucosal vaccine strategies. Her research also focuses on the long-term consequences of viral infections. She is the co-lead Investigator of the Yale LISTEN Study, which aims to determine the immunological features of long COVID. Dr. Iwasaki also leads multiple other studies to interrogate the pathobiology of long COVID.

In recognition of her distinguished scientific accomplishments, Iwasaki was elected to the National Academy of Sciences in 2018, National Academy of Medicine in 2019, American Academy of Microbiology in 2020, European Molecular Biology Organization in 2021, and American Academy of Arts and Sciences in 2021. She is the recipient of numerous additional honors, including receipt of the AAI-Thermo Fisher Meritorious Career Award and the AAI-BD Biosciences Investigator Award. Most recently, she was awarded the 2023 Else Kröner Fresenius Prize for Medical Research for her study of long COVID. The award also includes a prize committing \$2.5 million euros to further her investigation of post-acute infection syndromes such as long COVID and myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS).

In addition to her service on Council, Iwasaki has served as a member of the AAI Program Committee and AAI Nominating Committee, as an AAI President's Symposium speaker and major symposium chair and speaker at AAI annual meetings. She has also participated as a discussion leader at the Careers in Science Roundtable presented annually at the AAI meeting.

Her numerous additional career honors include receipt of the Connecticut Medal of Science; the Howard Taylor Ricketts Prize, University of Chicago; Yale Faculty Innovation Awards,

Yale Ventures; Elga R. Wasserman Courage, Clarity, and Leadership Award, Yale University; Helen Dean King Award, Wistar Women & Science Program, Wistar Institute; elected member of Council, Howard Hughes Medical Institute; Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research from the International Cytokine & Interferon Society; Eli Lilly and Company Research Award from the American Society for Microbiology, Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award, Wyeth Lederle Young Investigator Award from the Infectious Diseases Society of America, Ethel Donaghue Women's Health Program Investigator Award, Burroughs Wellcome Fund Career Award in Biomedical Sciences, Society for Mucosal Immunology Young Investigator Award, and election to the Connecticut Academy of Science and Engineering.

Iwasaki's dedication to advancing the immunology community extends to her active involvement on numerous journal editorial boards, advisory boards, and her advocacy for women in science, both through direct mentorship and advocacy. In addition, her extensive community outreach efforts, including her widely followed communications via social media, have contributed significantly to enhancing science understanding and trust on the part of the public. She was named one of the 50 top experts to trust during the pandemic by *Elemental*, a publication for science-backed health coverage, and was recently named to the annual STATUS List for 2023 published by the STAT online news outlet featuring fact-based journalism covering health, medicine, and the life sciences.

Upon assuming her role as 2023–2024 AAI president on July 1, Iwasaki expressed her gratitude, stating, "AAI has

been instrumental in shaping my professional journey as an immunologist. I am thrilled and honored to have this opportunity to give back to AAI and the broader immunology community through my service as president. I look forward to working with the dedicated members of our association to advance the field of immunology and address the pressing challenges facing our society. I am particularly excited to promote the next generation of immunologists."

"We are honored and excited to welcome Akiko Iwasaki as AAI's next president," said AAI Chief Executive Officer Loretta L. Doan, Ph.D., in marking the launch of Iwasaki's AAI presidential year. "Akiko's unwavering commitment to championing DEAI, her dedication to fostering the next generation of scientists, and her passion for educating the public about science are widely heralded and truly inspiring. Her vision will be instrumental in furthering AAI's mission at this critical juncture, and I look forward to working with her to bring that vision to life."

A native of Iga, Japan, Iwasaki is a biochemistry graduate (with physics minor) of the University of Toronto, where she obtained her Ph.D. in immunology in 1998. Her doctoral research focused on cytotoxic T lymphocyte induction by plasmid DNA immunization in the laboratory of Brian H. Barber. As a postdoctoral fellow in the laboratory of Brian Kelsall at the National Institute of Allergy and Infectious Diseases, she published a series of conceptual studies defining tissue-specific properties of dendritic cells.

Iwasaki joined the Yale School of Medicine as an assistant professor in 2000, becoming an associate professor in 2009 and full professor in 2011. She has been an HHMI investigator since 2014.



Iwasaki (pictured front row, 3rd from right) gathered with members of her lab

2023 AAI Election Results

AAI congratulates the following members on their election to the AAI Council and committees. All terms commenced July 1, 2023. AAI extends a sincere thanks to all candidates who agreed to stand for election. We thank them for investing in their profession and in the mission of AAI through their participation.

COUNCIL

President 2023–2024



Akiko Iwasaki, Ph.D., AAI '00

Sterling Professor of Immunobiology and Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology (Microbial Diseases); Director, Center for Infection and Immunity—Yale School of Medicine; Investigator—Howard Hughes Medical Institute

Vice President 2023–2024



Stephen Jameson, Ph.D., AAI '96

Professor and Chairman's Fund Professorship in Experimental Pathology, Center for Immunology—University of Minnesota, Twin Cities

Councilor 2023–2027



Maria-Luisa Alegre, M.D., Ph.D., DFAAI, AAI '97

Professor of Medicine, Section of Rheumatology, Department of Medicine; Member, Committee on Immunology—University of Chicago

COMMITTEES

Awards Committee 2023–2026



Christopher A. Hunter, Ph.D., AAI '96


Mindy Halikman Heyer Distinguished Professor of Pathobiology, Department of Pathobiology—University of Pennsylvania School of Veterinary Medicine

Finance Committee 2023–2026



Brian D. Evavold, Ph.D., AAI '94

George J. Weber Presidential Endowed Chair in Immunology; Professor, Department of Pathology; Chief, Division of Microbiology and Immunology—University of Utah School of Medicine



Nominating Committee 2023–2024



Erika L. Pearce, Ph.D., AAI '10—Chair
Bloomberg Distinguished Professor, Department of Oncology; Co-Director, Cancer Immunology Program—Johns Hopkins University (JHU) School of Medicine; Professor, Department of Biochemistry and Molecular Biology—JHU School of Public Health



Barbara L. Kee, Ph.D., AAI '04
Professor, Department of Pathology and Department of Family Medicine; Chair, Committee on Cancer Biology—University of Chicago



Gregory M. Barton, Ph.D., AAI '09
Professor of Immunology and Molecular Medicine, Department of Molecular and Cell Biology; Head, Division of Immunology and Molecular Medicine—University of California, Berkeley; Investigator—Howard Hughes Medical Institute



Laura Santambrogio, M.D., Ph.D., AAI '03
Associate Director, Precision Immunology—Englander Institute of Precision Medicine; Professor of Radiation Oncology and of Physiology and Biophysics—Weill Cornell Medicine



De'Broski R. Herbert, Ph.D., AAI '00
Presidential Professor of Immunology—University of Pennsylvania; Professor of Pathobiology—University of Pennsylvania School of Veterinary Medicine

Program Committee 2023–2026




Keke C. Fairfax, Ph.D., AAI '14
Associate Professor and Director of Equity, Diversity, and Inclusion, Division of Microbiology and Immunology, Department of Pathology—University of Utah



Elizabeth A. Leadbetter, Ph.D., AAI '10
Associate Professor, Department of Microbiology, Immunology & Molecular Genetics—UT Health, San Antonio

Publications Committee 2023–2027



Igor E. Brodsky, Ph.D., AAI '11
Robert R. Marshak Professor and Chair, Department of Pathobiology—University of Pennsylvania School of Veterinary Medicine; Associate Professor of Microbiology—Perelman School of Medicine, University of Pennsylvania

GOLD
circle
AWARDS
CELEBRATED BY ASAE




2023 Winner

The American Association of Immunologists Wins Top Awards for Excellence in Association Communications

AAI has been recognized by ASAE with two prestigious awards for its 2022 National Immunization Awareness Month Campaign! These include:

- the 2023 Gold Circle Award for Association Communications in Media/Public Relations and
- the 2023 Gold Circle Award for Overall Excellence in Association Communications.

The Gold Circle Awards competition is the premier association marketing, membership, and communications award that recognizes excellence, innovation, and achievement in association/nonprofit marketing, membership, and communications programs. This year's competition received more than 150 applications across 16 categories.



For more details, visit aai.org/PressRoom



AAI Urges Congress to Boost NIH Funding

AAI Committee on Public Affairs (CPA) Chair Peter Jensen, M.D. (AAI '87), submitted written congressional testimony on behalf of AAI to the Senate Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) Appropriations Subcommittee on May 17, after submitting similar testimony to the House in March. For fiscal year (FY) 2024, AAI recommends a National Institutes of Health (NIH) base budget (which supports NIH's regular operations) of at least \$51 billion and "substantial" funding for the Advanced Research Projects Agency for Health (ARPA-H).

As always, the AAI funding recommendation for the NIH base budget was developed in coordination with many other groups in the biomedical research community, including and most critically FASEB and the Ad Hoc Group for Medical Research (Ad Hoc Group). The joint recommendation of at least \$51 billion represents an increase of \$3.5 billion (7.3 percent) over FY 2023. In its testimony, AAI also requests that the "substantial" funding it recommends for ARPA-H supplement, and not supplant, the NIH base budget.

To view the full testimony submitted to the Senate, please visit <https://bit.ly/43QXLU9>.

President Biden Releases His Budget Request for FY 2024

On March 9, President Joe Biden unveiled his FY 2024 budget request, a highly detailed blueprint for federal spending that reflects his funding recommendations. Although Congress may consider a president's recommendations, Congress itself ultimately makes all discretionary funding decisions through the annual appropriations bills.

Despite President Biden's staunch support of NIH and biomedical research, his budget request seeks a very small \$800 million increase (1.7 percent) for the NIH base budget in FY 2024. His proposal would provide flat funding for most NIH Institutes and Centers, including the National Institute of Allergy and Infectious Diseases (NIAID). The President does seek to significantly ramp up investment in ARPA-H with a proposed \$1 billion increase (66.7 percent).

Last year, the President's budget included a very bold \$81 billion pandemic preparedness proposal that was endorsed by AAI. His FY 2024 budget request includes a significantly scaled back version of that proposal, calling for \$20 billion in mandatory funding for these activities, including \$2.69 billion for NIH.

New Debt Ceiling Law Significantly Restricts Federal Spending for Nondefense Programs

On June 3, President Biden signed into law the Fiscal Responsibility Act of 2023 (FRA), a bipartisan measure that, among other things, suspends the federal debt limit, places caps on discretionary spending, and rescinds some unspent COVID-19 funds. The new law is the product of long negotiations between Democrats and Republicans, mostly notably between President Biden and Speaker of the House Kevin McCarthy (R-CA, 20th).

Crucially, the FRA suspends the federal debt limit until January 2, 2025. Shortly before the enactment of this legislation, the nation was on the verge of breaching the debt ceiling, threatening the United States' ability to meet its fiscal obligations and endangering the country's credit rating. However, Speaker McCarthy and many other Congressional Republicans had indicated that they were unwilling to lift or suspend the debt limit unless it was paired with cuts to nondefense spending (a very broad category that includes, but is not limited to, programs related to medical research, health, transportation, immigration, housing, and labor). As a result, the new law does significantly restrain spending in this category.

According to the White House, the FY 2024 cap on nondefense spending, excluding funding for veterans' programs, will be \$637 billion, \$1 billion below the amount that was appropriated for FY 2023. For FY 2025, the cap will increase by just one percent to approximately \$643.5 billion. Under these caps, it will be very difficult for Congress to increase funding for any nondefense agencies and programs, including NIH, and any increases that are provided will likely result in cuts to other parts of the federal government. Defense spending, however, will increase by three percent in FY 2024 to \$886 billion and by one percent in FY 2025 to \$895 billion.

The FRA also rescinds about \$30 billion in unspent funding originally appropriated to combat the COVID-19 pandemic. However, it has been widely reported that the \$5 billion in COVID-19 funding that was recently allocated to launch Project NexGen, which aims to expedite the development of new COVID-19 vaccines and treatments, will not be rescinded.

In spite of these fiscal challenges, AAI will continue to advocate for the increases it believes research agencies need to operate well, including appropriating at least \$51 billion for NIH and providing substantial funding for ARPA-H for FY 2024.

AAI Hosts 12th Annual PFPF Capitol Hill Day

The nine 2022-23 AAI Public Policy Fellows Program (PFPF) participants, together with CPA Chair Jensen and Advocacy Programs Subcommittee Chair Gretchen Diehl, Ph.D., traveled to Washington, DC, for a two-day Capitol Hill Day program in March. The group convened for a dinner on March 21 featuring remarks by Acting NIAID Director Hugh Auchincloss, M.D., DFAAI (AAI '83), who has spoken at this event every year since the program's inception. The dinner also included presentations by AAI Chief Policy and Program Officer Lauren Gross, J.D., and AAI Director of Public Policy and Government Affairs Jake Schumacher, to further prepare the Fellows for their upcoming Hill visits.

On March 22, the Fellows visited 25 Congressional offices, including meetings with five Senators and three Members of Congress. Throughout the day, the Fellows communicated the importance of immunological research and increased funding for NIH, AAI support for ARPA-H, the ongoing challenges of COVID-19 (including the need for next-generation vaccines and treatments), and the importance of preparing for the next pandemic.



Pictured from left: Erin Taylor, Senator Jon Ossoff (D-GA), Ninecia Scott, Victoria Mutua, and Schumacher



Pictured from left: Chandra Menendez and Senator James Lankford (R-OK)



Pictured from left: Ninecia Scott, Adriana Benavides, Chandra Menendez, Adeleye Adeshakin, Gretchen Diehl, Jeremy Crawford, Victoria Mutua, Auchincloss, AAI CEO Loretta Doan, Gross, Erin Taylor, Schumacher, Caroline Jones, AAI Science Policy Analyst Emily Kansler, Jamie McCall, and Jensen

IMMUNOLOGY2024™

THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

MAY 3–7, 2024 | CHICAGO, ILLINOIS

IMMUNOLOGY2024.AAI.ORG



Call for 2024 Award Nominations

Deadline: September 20, 2023

Nominations are invited for the following AAI Career Awards. These awards honor immunologists of extraordinary scientific achievement and promise.

AAI Members! Don't miss the opportunity to nominate a worthy colleague for awards that are among the leading professional honors presented annually to immunologists!

AAI-BioLegend Herzenberg Award

Established to honor the memory of AAI member Leonard A. Herzenberg, Ph.D., this award recognizes an individual who has made exemplary research contributions to the field of B cell biology. The award recipient will receive a \$5,000 cash award, meeting registration, and travel support to the AAI annual meeting. The recipient will present their research in an award lecture.

AAI Excellence in Mentoring Award

This award recognizes a senior scientist who has significantly influenced the professional development and careers of a new generation. AAI honors the award recipient's contributions to the profession through outstanding mentoring. The award includes a plaque, meeting registration, and travel support to the AAI annual meeting. This award is presented at an awards presentation program at the AAI annual meeting.

AAI-Steinman Award for Human Immunology Research

This award recognizes an individual who has made significant contributions to the understanding of immune processes underlying human disease pathogenesis, prevention, or therapy. The award recipient will receive a \$5,000 cash award, meeting registration, and travel support to the AAI annual meeting. The recipient will present their research in an award lecture.

AAI-Thermo Fisher Meritorious Career Award

This award recognizes a mid-career scientist for outstanding research contributions to the field of immunology. The award recipient will receive a \$10,000 cash award, meeting registration, and travel support to the AAI annual meeting for presentation of their research in an award lecture.

AAI-BD Biosciences Investigator Award

This award recognizes an early-career investigator who has made outstanding contributions to the field of immunology. The awardee will receive a \$5,000 cash prize, meeting registration, and travel support to the AAI annual meeting for presentation of their research in an award lecture.

NEW! AAI Lancefield Mid-Career Achievement Award

This award recognizes an outstanding mid-career woman investigator for research and leadership within the field of immunology. The awardee will receive a \$5,000 cash award, meeting registration, and travel support to the AAI annual meeting for presentation of their research in an award lecture.

For complete AAI Career Award nomination details, as well as information on applying for AAI Travel Awards and Grants, visit www.AAI.org/Awards.

The 2024 AAI Awards will be presented in conjunction with

IMMUNOLOGY2024™ • May 3–7, 2024 • Chicago, IL
Questions? Contact AAI at 301-634-7178 or awards@aai.org

AAI Announces 2023–24 Public Policy Fellows

AAI recently announced the 13th class of AAI Public Policy Fellows, who began their one-year fellowship on May 1, 2023. The AAI PFP engages early career researchers in AAI advocacy activities focused on increasing biomedical research funding, strengthening the research enterprise, and advancing the understanding of—and support for—immunology. Following careful review of the applications received, the AAI CPA selected the following 10 individuals to participate in the 2023–24 PFP:



Mafalda de Arrábida Farelo, Ph.D. (AAI '23)

University of California Riverside



Srinivasu Mudalagiriappa, D.V.M., Ph.D. (AAI '19)

Insmed, Inc.



Heather Gustafson, Ph.D. (AAI '20)

Seattle Children's Research Institute



Amali Samarasinghe, Ph.D. (AAI '07)

University of Tennessee Health Sciences Center



Anne Hahn, Ph.D. (AAI '23)

Yale School of Public Health



Derek Theisen, Ph.D. (AAI '23)

Washington University in St. Louis



Emma Hornick, Ph.D. (AAI '21)

University of Iowa



Sarah Webster, Ph.D. (AAI '21)

Western Michigan University Homer Stryker M.D. School of Medicine



Nicholas Maurice, Ph.D. (AAI '16)

University of Minnesota



Samantha Yeligar, Ph.D. (AAI '21)

Emory University

For complete PFP details, including program goals and description, and to view Fellows from previous years, visit www.aai.org/PFP.

Biden Announces Intent to Nominate Dr. Monica Bertagnolli as NIH Director

On May 15, President Biden announced his intent to nominate Monica Bertagnolli, M.D., as the next NIH director. Dr. Bertagnolli is the first woman to serve as the director of the National Cancer Institute, a role she has held since October 2022. In response to the announcement, AAI President Mark M. Davis, Ph.D. (AAI '88), issued the following statement:

“AAI is delighted that President Biden has announced his intent to nominate Dr. Monica Bertagnolli to be the next director of the National Institutes of Health (NIH). In her short tenure as head of the National Cancer Institute, and before that as a professor, surgical oncologist, and physician-scientist whose research included tumor immunology, Dr. Bertagnolli has demonstrated leadership, vision, understanding, and compassion. AAI enthusiastically supports her nomination and is confident that she will be able to lead NIH, the broader biomedical workforce, and the American people into the future—with all the amazing scientific possibilities that lie ahead.”

Bertagnolli's nomination will need to be approved by the Senate. If confirmed, she will take the helm from Lawrence Tabak, D.D.S., Ph.D., who has served as the temporary leader of NIH since December of 2021. The next NIH director will face a multitude of challenges, including numerous Congressional investigations, a dramatic increase in public distrust of science, and a difficult funding landscape as a result of the recently passed Fiscal Responsibility Act of 2023.

AAI Comments on NIH Plan to Simplify Peer Review Criteria

AAI submitted comments to NIH in early March in response to its Request For Information (RFI) entitled, “Proposed Revised Simplified Review Framework for NIH Research Project Grant Applications.” In the comments, AAI expresses support for “the proposal developed by the Center for Scientific Review to simplify the current peer review framework to refocus reviewers' attention on evaluating the scientific merit of grant applications.”

One of the major changes in the proposed framework is to consolidate the five currently scored criteria of significance, innovation, approach, investigator, and environment, into three factors:

1. Importance of the Research (previously “significance” and “innovation”)
2. Rigor and Feasibility (previously “approach”)
3. Expertise and Resources (previously “investigator” and “environment”)

The first two factors would be individually scored, while factor three would not be scored and instead be evaluated as “appropriate” or “gaps identified,” the latter of which would require written justification.

In its comments, AAI expresses support for this effort to reduce implicit bias and guide reviewers to evaluate investigators and their environments in the context of the science, rather than on reputations or preconceived notions. AAI also expresses appreciation that the revised proposed framework aims to reduce administrative burden. Finally, AAI urges NIH to develop a clear and well-organized implementation plan that includes timely and adequate training for all involved.

To view the full AAI comments, please visit <https://bit.ly/3oUjRWX>.

AAI Submits Comments on Re-envisioning Postdoctoral Training in Academia

AAI submitted comments to NIH in mid-April in response to its RFI on “Re-envisioning U.S. Postdoctoral Research Training and Career Progression within the Biomedical Research Enterprise.” The AAI comments outline some of the current challenges and barriers that academic postdocs are facing, including insufficient pay, lack of adequate benefits and accommodation of family responsibilities, and uncertainty about future career prospects.

In its comments, AAI encourages NIH to consider modifying or expanding programs that would improve the postdoctoral training ecosystem, including allowing National Research Service Award (NRSA) fellows and trainees to maintain “employee” status at their institutions so they can continue receiving institutional benefits like health insurance. AAI also expresses the view that NIH should develop and enhance mentoring opportunities, expand funding mechanisms that bridge postdocs to academic careers, and explore existing and new programs that enable postdocs to obtain and thrive in the careers of their choice. AAI also emphasizes the need for NIH to work with other federal agencies to facilitate the recruitment and retention of qualified international scientists and provide needed support to international scientists currently studying or working in the United States (for example, by providing assistance with the visa process).

AAI's comments, together with those submitted by other interested organizations and individuals, will help inform the NIH Advisory Committee to the Director Working Group on “Re-envisioning NIH-Supported Postdoctoral Training” as it develops its final recommendations, which are expected to be unveiled in December.

To view the full AAI comments, please visit <https://bit.ly/43stfQE>.

AAI Responds to Draft NIH Public Access Plan

AAI recently submitted comments on NIH's draft Public Access Plan, which was released on February 21, 2023. The draft plan was NIH's response to a memo issued in August 2022 by the White House Office of Science and Technology Policy entitled, “Ensuring Free, Immediate, and Equitable Access to Federally Funded Research.” This memo instructs federal agencies that fund scientific research to update their

public access policies no later than December 31, 2025, “to make publications and their supporting data resulting from federally funded research publicly accessible without an embargo on their free and public release.”

AAI’s comments urge NIH to proceed slowly and thoughtfully, with full consideration given to the impact that the plan could have on not-for-profit scientific society publishers. Scholarly publishers like AAI often depend on revenue generated by their journals to provide scientific peer review and editing and to invest heavily to ensure that access to scientific information is accurate and reliable. This net revenue also helps to support scholarly society programs and activities that advance their dedicated scientific fields and support their members. AAI also calls attention to the potentially deleterious impact that a fully open-access publishing model, which would likely increase publication costs for authors, may have, especially on under-resourced investigators and institutions. AAI urges NIH to provide comprehensive guidance on all ways investigators can charge publication costs.

To view the full AAI comments, please visit <https://bit.ly/42vTkgl>.

AAI Submits Comments to NIAID in Response to its Request for Information on DEIA

AAI submitted comments to NIAID in late May in response to its RFI, “Seeking Stakeholder Input on Enhancing Diversity, Equity, Inclusion, and Accessibility (DEIA) Across NIAID Extramural Activities.” NIAID specifically requested feedback on how to enhance DEIA in NIAID research areas, NIAID organizational practices, and in extramural scientific workforce diversity.

Among other things, AAI urges NIAID to conduct research across diverse patient profiles for all illnesses, appreciate the value of community-based research, and “evaluate the strengths and or/capabilities of an individual or institution in DEIA efforts” in funding decisions. In this regard, AAI suggests that NIAID consider participating in the new Research with Activities Related to Diversity program, which provides support for scientists conducting health-related research who are making a significant contribution to DEIA and have no current NIH Research Project Grant funding. AAI also encourages NIAID to consider ways to assess and enhance success rates of historically excluded groups and reinforces the need to foster meaningful mentorship relationships.

To view the full AAI comments, please visit <http://bit.ly/3quu399>.

Recognizing research and leadership achievements of women in immunology

The AAI Lancefield Mid-Career Achievement Award

Sponsored by the AAI Committee on the Status of Women

For more information, please visit www.aai.org/Lancefield.



Application cycle opens: August 1, 2023 • Application deadline: September 20, 2023

Iwasaki Awarded the Else Kröner Fresenius Prize for Medical Research 2023 and Named to 2023 STATUS List



Akiko Iwasaki, Ph.D. (AAI '00), has received the Else Kröner Fresenius Prize for Medical Research 2023 and was named to the 2023 STATUS List.

Dr. Iwasaki is a Sterling Professor of Immunobiology and Molecular, Cellular, and Developmental Biology at Yale University and an HHMI Investigator. She has been selected for

the Else Kröner Fresenius Prize for Medical Research, one of the world's most highly endowed prizes for research in the field of medicine, for her groundbreaking contributions in the area of "diseases of worldwide significance" for her work on immune responses to viral infections. The prize will further her investigation of post-acute infection syndromes such as long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

She was also named to STAT's annual list of standout individuals in health, medicine, and science. This year's STATUS List included 46 individuals for excellence in their fields, and Iwasaki was selected in the area of academia.

Iwasaki's research focuses on understanding how viruses infect the host through the mucosal surfaces to cause diseases; how the immune system deals with viral infections within these local tissues; how acute infections lead to long-term diseases; and how to use such insights to design vaccines and therapeutics against acute and chronic viral diseases, post-viral diseases, autoimmunity, and cancer.

To learn more about her research, visit <https://medicine.yale.edu/profile/akiko-iwasaki>.

Read the full announcements at www.ekfs.de/en/current-topics/press/invitation-press-akiko-iwasaki-awarded-else-kroner-fresenius-prize-medical and at www.statnews.com/status-list/2023.

Belkaid Appointed Director General of the Institut Pasteur



Yasmine Belkaid, Ph.D. (AAI '13), was appointed director general of the Institut Pasteur by its board of directors for a six-year term. The Institut Pasteur is a privately funded nonprofit foundation committed to fighting infectious disease through extensive research, educational endeavors, and public health initiatives.

Dr. Belkaid is the chief of the Metaorganism Immunity Section and chief of the Laboratory of Host Immunity and Microbiome at the National Institute of Allergy and Infectious Diseases (NIAID), NIH. Dr. Belkaid studies how commensal microbiota and pathogens interact with host barriers to result in inflammation or tolerance. Her laboratory studies this delicate dichotomy: immune tolerance of innocuous microbiota and robust and rapid response to pathogenic challenges. For more information about her research, visit www.niaid.nih.gov/research/yasmine-belkaid-phd.

Read the full announcement at www.pasteur.fr/fr/espace-presse/documents-presse/professeure-yasmine-belkaid-est-nommee-directrice-generale-institut-pasteur.

Jaffee Receives the AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research



Elizabeth M. Jaffee, M.D., FAACR (AAI '97), has received the American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research.

Dr. Jaffee is the Dana and Albert "Cubby" Broccoli Professor in oncology and deputy director of the Sidney

Kimmel Comprehensive Cancer Center at Johns Hopkins University, as well as inaugural director of the Convergence Institute and associate director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy. She is also a professor of pathology at the Johns Hopkins University School of Medicine, co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care, and deputy director of the Johns Hopkins Institute for Clinical and Translational Research. This award recognizes exceptional individuals who champion cancer research, showcasing their outstanding

leadership and remarkable accomplishments that have significantly influenced the field. Jaffee is being recognized for her exceptional leadership, extraordinary record of service to the cancer community, and pioneering research discoveries, including the development of innovative approaches to antigen discovery and the identification of two novel pancreatic cancer proteins that are promising targets for immunotherapy, mesothelin, and Annexin A2.

Jaffee's research is focused on the development of novel vaccine approaches that overcome immune tolerance to cancers. For more information about her research, visit www.hopkinsmedicine.org/profiles/details/elizabeth-jaffee.

Read the full announcement at www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-announces-recipients-of-its-2023-scientific-achievement-awards-lectureships-and-prizes.

Wherry Receives the AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology



E. John Wherry, Ph.D. (AAI '05), has received the AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology.

Dr. Wherry is chair of the Department of Systems Pharmacology and Translational Therapeutics, director of the Institute for Immunology, and founding director of the Immune

Health Project in the Perelman School of Medicine at the University of Pennsylvania. The award recognizes his essential cancer immunology research findings dedicated to defining the genetic and epigenetic control mechanisms of T cell exhaustion that have contributed to the elucidation of PD-L1 blockade and helped guide the development of immunotherapy treatments for cancer patients, including several FDA-approved checkpoint inhibitor therapies for multiple cancer indications. For more information about his research, visit www.med.upenn.edu/wherrylab.

Read the full announcement at www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-announces-recipients-of-its-2023-scientific-achievement-awards-lectureships-and-prizes.

Schietinger Receives AACR-Irving Weinstein Foundation Distinguished Lectureship



Andrea Schietinger, Ph.D. (AAI '14), received the AACR-Irving Weinstein Foundation Distinguished Lectureship.

Dr. Schietinger is an associate member of the Immunology Program at Memorial Sloan Kettering Cancer Center and an associate professor of Immunology & Microbial Pathogenesis at Weill Cornell Medical College in

New York. She received this lectureship for her unparalleled contributions to elucidating the fundamental cellular mechanisms of immune evasion, including demonstrating

how antigen-specific T cells evade immune-suppressive mechanisms in normal tissues, which has subsequently fueled the development of innovative strategies for molecular and immune-based targeted therapies for the treatment of cancer. For more information about her research, visit www.mskcc.org/research/ski/labs/andrea-schietinger.

Read the full announcement at www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-announces-recipients-of-its-2023-scientific-achievement-awards-lectureships-and-prizes.

Schreiber Receives AACR-Princess Takamatsu Memorial Lectureship




Robert D. Schreiber, Ph.D., FAACR (AAI '76), received the AACR-Princess Takamatsu Memorial Lectureship.

Dr. Schreiber is the Andrew M. and Jane M. Bursky Distinguished Professor in the Department of Pathology and Immunology and director of the Bursky Center for Human Immunology and Immunotherapy Programs at the

Washington University School of Medicine. He is recognized for his indelible research findings at Siteman Cancer Center that have led to an improved understanding of immune surveillance in cancer pathogenesis, including the definition of the physiologic roles and mechanisms of action of Type I interferon and interferon gamma in cancer-associated immune responses, and for establishing the concept of "immunoediting" that has since fueled the development of cancer immunotherapeutics. For more information about his research, visit <https://pathology.wustl.edu/people/robert-schreiber-phd>.

Read the full announcement at www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-announces-recipients-of-its-2023-scientific-achievement-awards-lectureships-and-prizes.

Mitchell Named Among 31 Freeman-Hrabowski Scholars



Patrick Mitchell, Ph.D. (AAI '21), was named among 31 inaugural Freeman-Hrabowski Scholars.

This honor recognizes exceptional early career science faculty members who exhibit remarkable potential to emerge as leaders in their research fields and to create diverse and inclusive lab environments.

Dr. Mitchell is an assistant professor at the University of Washington. His work is aimed at uncovering strategies that animal cells use to specifically detect pathogens via the innate immune detection of activities that are unique to pathogens. To learn more about his research, visit <https://mitchelllabuw.com>.

Read the full announcement at www.hhmi.org/news/hhmi-names-31-inaugural-freeman-hrabowski-scholars.

Lunney Receives 2022 Presidential Rank Award and 2023 Distinguished Veterinary Immunologist Award



Joan Lunney, Ph.D. (AAI '80), received the 2022 Presidential Rank Award and the 2023 Distinguished Veterinary Immunologist Award.

Dr. Lunney is a supervisory research scientist at the Animal Parasitic Diseases Laboratory.

Last Fall, President Biden selected the 2022 Presidential Rank Award winners.

Lunney was one of the esteemed winners, recognized as a "Meritorious Senior Professional" for her research at the USDA-ARS' Beltsville Agricultural Research Center. The award is considered the highest honor for career civil servants. The Distinguished Veterinary Immunologist Award honors internationally recognized immunologists who have become an authority and leader in the field of Veterinary Immunology. Her research is centered on exploring pig responses to highly infectious diseases. Based on a genomics approach to research, she has delineated critical immune genes and the major histocompatibility complex, the swine

leukocyte antigen (SLA) complex genes. To learn more about her research, visit www.ars.usda.gov/people-locations/person/?person-id=3471.

Read the full announcements at www.opm.gov/policy-data-oversight/senior-executive-service/presidential-rank-awards/2022/presidential-rank-awards-2022.pdf and <https://ivis2023.org/dvi-award-copy>.

Six AAI Members Elected to the National Academy of Sciences

The following AAI members were elected to the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research.

AAI congratulates the following:

- Jeffrey A. Bluestone, Ph.D. (AAI '82)
- Lisa M. Coussens, Ph.D. (AAI '14)
- Philip Greenberg, M.D. (AAI '82)
- Jeffrey A. Hubbell, Ph.D. (AAI '22)
- John J. O'Shea, M.D. (AAI '84)
- Ulrich von Andrian, M.D. (AAI '97)

Read the full announcement at <http://nasonline.org/news-and-multimedia/news/2023-nas-election.html>.

Connect with AAI!

Want to hear the latest from The American Association of Immunologists? You can find AAI and its journals, *The Journal of Immunology* and *ImmunoHorizons*, through your favorite social media channels:



@ImmunologyAAI



@AAIImmunology



[linkedin.com/company/the-american-association-of-immunologists/](https://www.linkedin.com/company/the-american-association-of-immunologists/)



The Journal of Immunology



@J_Immunol



ImmunoHorizons



@ImmunoHorizons

If you'd like to join the AAI email list, please email infoaai@aai.org.

AAI use of any social media site/platform does not constitute AAI endorsement or approval of the opinions expressed by the owners, founders, CEOs, leadership, or other users of these sites/platforms.



Photo credit: Dr. Dody Bienenstock

John Bienenstock, FRCP, FRCPC, FRSC (AAI '69)

October 6, 1936 – July 25, 2022

AAI extends sincere condolences to the family, friends, and colleagues of McMaster Brain Body Institute Director John Bienenstock, FRCP, FRCPC, FRSC (AAI '69), who died on July 25, 2022.

The following tribute to Dr. Bienenstock was authored by colleague Dr. Pearay Ogra, M.D. (AAI '72), emeritus professor, State University of New York at Buffalo, and John Sealy Distinguished Chair and professor and chairman emeritus, pediatrics, University of Texas, Medical Branch.

Dr. John Bienenstock, an internationally renowned visionary physician, scientist, academic, and leader at McMaster University, passed away on July 25 at the age of 85. Born in Budapest, Hungary, in 1936, he obtained his medical degree from King's College London and Westminster Hospital Medical School in the United Kingdom in 1960. Following a postdoctoral term at Harvard University and additional training at the State University of New York at Buffalo with professor T. B. Tomasi, he joined the faculty of McMaster University's medical school start-up in Ontario, Canada, in 1968, with the first class commencing in 1969.

Although officially retiring as a professor of pathology in 1998, John remained actively engaged in his research and served as the director of the McMaster Brain Body Institute at St. Joseph's Healthcare Hamilton until his passing. Throughout his tenure at McMaster, he achieved worldwide recognition as a pioneer in the field of mucosal immunology, introducing the concept of a common mucosal immune system. His groundbreaking research also advanced the understanding of neuroimmunology and the collaboration between the brain and nervous system. With an impressive publication record, John authored, edited, or co-edited 10 books, including a widely regarded textbook on mucosal immunology and allergy. Additionally, he published more than 500 peer-reviewed articles, solidifying his position as a prominent figure in the scientific community.

John's influence extended beyond his research endeavors. He served as the chair of the Department of Pathology from 1978 to 1989 and later held the positions of dean and vice president

of the Faculty of Health Sciences at McMaster from 1989 to 1997. During his time as an administrator, he played a pivotal role in establishing a robust research infrastructure within the faculty.

Over the years, John's exceptional contributions were duly acknowledged and honored. In 1992, he was elected as a Fellow of the Royal Society of Canada, followed by the recognition of becoming a McMaster Distinguished University Professor in 1999. He was also appointed as a member of the Order of Canada in 2002 and was inducted into the Canadian Medical Hall of Fame in 2011. In 2014, he became a member of the Faculty of Health Sciences Community of Distinction. Furthermore, he received an honorary M.D. from the Institute of Medicine, University of Gothenburg, Sweden, further solidifying his extensive accolades.

John is survived by his beloved family, including his wife Dody; their children, Adam (Jill), and Robin; as well as their cherished grandchildren, Bella, Elsa, Sam, Leo, Sebastiano, and Oliva. He is also survived by his sister Tsultrim Zangmo (Veronica). His son Jimson (Johanna) preceded him in death.

John's impact on McMaster University and the broader scientific community is immeasurable. His visionary approach as a scientist, administrator, and academic inspired generations of scientists and clinicians to think outside the box and strive for innovation. He was not only a respected colleague but also a friend and mentor to many. His legacy will continue to shape the future of scientific exploration, and his memory will be cherished by all those whose lives he touched.



Thomas J. Braciale, M.D., Ph.D. (AAI '80)

October 22, 1946 – May 19, 2023

AAI extends sincere condolences to the family, friends, and colleagues of University of Virginia (UVA) Professor of Pathology and Microbiology Thomas J. Braciale, M.D., Ph.D. (AAI '80), who died on May 19, 2023.

During his 43 years of AAI membership, Dr. Braciale was a major symposia speaker at AAI annual meetings and served as an associate editor and section editor for The Journal of Immunology.

The following tribute to Braciale was authored by Jennifer T. Aminuddin for UVA's "Medicine in Motion News" and is reprinted here with the kind permission of the author.

It is with great sadness the School of Medicine shares news about the passing of a dear friend and colleague, Thomas J. Braciale, M.D., Ph.D. Dr. Braciale passed away Friday, May 19, 2023, with his family at his side.

Dr. Braciale was a globally recognized authority in the field of immunology, a professor at the University of Virginia (UVA) in pathology and microbiology for over three decades and founding director of the Beirne B. Carter Center for Immunology Research (CIC). His work in the areas of T cells, dendritic cells, and respiratory immunity established him as an impactful leader in immunological research.

Tom was the first member of his family to earn a college degree, obtaining his bachelor's degree in science from St. Joseph's University. He went on to receive M.D. and Ph.D. (microbiology) degrees from the University of Pennsylvania. After completing a residency in pathology at Washington University in St. Louis, he began his career in academic medicine and research there, quickly establishing himself as a leader in discovering molecular and cellular mechanisms that underlie pathogen-host interactions, most notably the interplay between influenza virus, respiratory epithelium, and immune cells. He rose to the rank of tenured professor at Washington University and was then recruited to UVA to take the role of director of the Beirne B. Carter Center for Immunology Research and to join the Department of Pathology at the rank of professor.

He had a productive and distinguished career, having authored over 180 publications and winning several awards, including the Eijkman Medal for Immunology and Infectious Diseases from Utrecht University in 2002. Tom served on several advisory boards and committees at peer institutions, national organizations and the Federal Government, including U-19 scientific advisory committees at the University of North Carolina, Wake Forest University, and the Milwaukee Blood Center, and several advisory committees for the National Institute of Allergy and Infectious Disease, including memberships on the Oversight Committee of the NIAID Center of Excellence in Influenza Research and Surveillance and the Board of Scientific Counselors of

the NIAID Vaccine Research Center. In addition, he served as associate editor for four scientific journals: *Clinical & Experimental Immunology*, *Immunology and Cell Biology*, *Virology*, and *Molecular Biology and Medicine*.

Throughout his extraordinary career in research, he remained committed to education, imparting knowledge to undergraduate, graduate, postdoctoral fellows, and medical students. He was most proud of his role as an educator and mentor, serving as research mentor for many Ph.D. graduate students and postdoctoral fellows in his laboratory and participating in the UVA School of Medicine Biomedical Sciences Training Program. He was generous in his time with his colleagues and served as mentor to many junior faculty. He will be remembered gratefully for guiding the Carter Center to national prominence through his recruitment of world-class faculty and his own research efforts.

Tom will be deeply missed by his colleagues and friends in the School of Medicine Departments of Pathology; Microbiology, Immunology, and Cancer Biology; Beirne B. Carter Center for Immunology Research; and across the University and world. As a leader within the UVA immunology community, he cultivated a collaborative and groundbreaking atmosphere that has continuously driven the progress of immunology research at UVA.

Visitation was held on June 2, 6-8 p.m. at Teague Funeral Services 2260 Ivy Road, Charlottesville. A Funeral Mass occurred on June 3 at 11:00 a.m. at St. Thomas Aquinas Church 401 Alderman Road, Charlottesville. A reception followed at Boars Head in the Pavilion. More details can be found at www.dignitymemorial.com/obituaries/charlottesville-va/dr-thomas-braciale-11297834.

To commemorate Dr. Braciale's lasting influence at the UVA School of Medicine, a scholarship fund has been established to support aspiring first-generation college students, like Dr. Braciale, who are pursuing careers in the biological sciences. The family requests that in lieu of flowers, contributions be made to this scholarship fund: www.immunology.virginia.edu/thomas-braciale-scholarship.

AAI Announces Winter 2023 Travel for Techniques Awardees

AAI is pleased to announce the most recent **AAI Travel for Techniques Award** recipients, selected from among applicants during the program's Winter 2023 application cycle.

The AAI Travel for Techniques Program assists member principal investigators (regular or associate) in expanding their skill sets to benefit their research. Selected applicants may use the award to travel themselves, assign the award to a trainee in their lab, or assign the award to another lab member. AAI reimburses award recipients as much as \$1,500 in travel expenses incurred on a trip to another laboratory to learn a technique.

AAI extends congratulations to:



Pucci and Guo

Ferdinando Pucci, Ph.D. (AAI '20)

Assistant Professor

Oregon Health and Science University

Designated Traveler:

Zihan Guo (AAI '22), graduate student

Destination: The laboratory of Dr. Thomas Murooka, University of Manitoba, Canada

Technique: Multiphoton-intravital microscopy of mouse popliteal lymph nodes

Application: To study the interactions between antigen-specific B cells with helper T cells in the context of cancer



Warren and Sanders

Cody J. Warren, M.P.H., Ph.D. (AAI '23)

Assistant Professor

The Ohio State University

Designated Traveler: Christina G. Sanders (AAI '23), graduate student

Destination: The laboratory of Dr. Sara Sawyer, University of Colorado, Boulder

Technique: Production of human-induced pluripotent stem cell (iPSC)-derived macrophages

Application: To provide a physiologically relevant *in vitro* model to better understand various aspects of viral infection, including host cell-intrinsic antiviral immunity

Travel for Techniques Award applications are reviewed in three cycles annually—winter, spring, and fall. Fall cycle applications will be accepted from August 15 through October 17. Full details are available at www.aai.org/TravelForTechniques.

AAI Fellowship Program for Career Reentry



Fellowship Overview

This fellowship program provides one year of salary support to postdoctoral fellows who have taken a leave of absence of one year or more due to military obligations, personal or family medical leave, or other related family circumstances. These reasons may include recovering from a serious illness, providing elder or child care, fulfilling a military obligation, or relocating due to a spousal career transition.

Eligibility

- An applicant must have a tentative written offer of appointment as a postdoctoral fellow.
- The fellowship must be in immunology or a related field.

Award consideration is based on a combination of the merit of the research project, quality of the training environment, research and career accomplishments, and career potential.

APPLICATIONS OPEN **JUNE 1**
APPLICATIONS CLOSE **SEPTEMBER 6**



**For more information or to apply, visit www.aai.org/Reentry.
Please direct inquiries to fellowships@aai.org.**

If the application deadline falls on a weekend day or a federal holiday, applications will be due on the next regular business day.



AAI Intersect Fellowship Program for Computational Scientists and Immunologists

Fellowship Overview

Recognizing the vital role cross-trained scientists play in furthering immunology research, this fellowship program is intended to promote understanding and communication between immunology researchers and computational scientists. A PI may apply for a one-year fellowship, which will support a postdoctoral fellow trained in basic bench research to train in computational science, or a postdoctoral fellow in computational science to train in an immunology research lab to learn basic immunological principles and laboratory techniques. Reciprocal six-month exchanges between labs will also be considered.

APPLICATIONS OPEN	JUNE 1
APPLICATIONS CLOSE	SEPTEMBER 6

Eligibility

One of the collaborating PIs must be an AAI member in good standing. If the PI is a research immunologist, he/she must be independent. Applicants may request salary support for a maximum of one postdoctoral fellow for one year, or two postdocs for six months each.

Trainees must be in years one through five of postdoctoral training in the physical/mathematical/computational sciences, immunology, or related fields. Postdoctoral fellows who have completed five years of training and transitioned into a second postdoctoral position will be considered on a case-by-case basis.

Review Process

Award consideration is based on a combination of the qualifications of the applicant, the merit of the PI's proposed project, the potential of the trainee, and the quality of the training environment.

For more information or to apply, visit www.aai.org/Intersect.


Please direct inquiries to fellowships@aai.org.

If the application deadline falls on a weekend day or a federal holiday, applications will be due on the next regular business day.

AAI Congratulates Recipients of 2023 Intersect Fellowships for Computational Scientists and Immunologists

AAI congratulates nine members selected to receive AAI Intersect Fellowships in 2023. The AAI Intersect Fellowship Program for Computational Scientists and Immunologists provides independent research scientists with one year of salary support for postdoctoral fellows trained in basic bench research to undertake one year of training in computational science, or postdoctoral fellows trained in computational science to spend one year in an immunology research lab to learn basic immunological principles and laboratory techniques. To learn more about this program, visit www.aai.org/IntersectFellowship.

The awardees selected for the 2023 Intersect Fellowships are:



From left: Di Pilato, Kugeratski, and Li

Mauro Di Pilato, Ph.D. (AAI '22)


Assistant Professor

The University of Texas M.D. Anderson Cancer Center

Postdoctoral Fellow: Fernanda Grande Kugeratski, Ph.D. (AAI '22)

Co-PI: Ziyi Li, Ph.D., assistant professor,
The University of Texas M.D. Anderson Cancer Center

Project Title: Pinpointing the CCR7+ dendritic cells on the tumor map



From left: Huttenlocher, Hou, and Dinh

Anna Huttenlocher, M.D. (AAI '10)


Professor

University of Wisconsin, Madison

Postdoctoral Fellow: Yiran Hou, Ph.D. (AAI '22)

Co-PI: Huy Dinh, Ph.D. (AAI '22), assistant professor,
University of Wisconsin, Madison

Project Title: Understanding subset contributions in neutrophil reverse migration and resolution of inflammation



From left: Herbert, Musaigwa, and Reed

De'Broski R. Herbert, Ph.D. (AAI '00)


Professor

University of Pennsylvania

Postdoctoral Fellow: Fungai Musaigwa, Ph.D. (AAI '22)

Co-PI: Danielle R. Reed, Ph.D., associate director,
Monell Chemical Senses Center

Project Title: Perforin-2 expressing APC are responsible for unconventional cytokine release



From left: Martins, Dos Santos, and Vujkovic-Cvijin

Gislaine A. Martins, Ph.D. (AAI '08)

Associate Professor


Cedars Sinai Medical Center

Postdoctoral Fellow: Jessica C. Dos Santos, Ph.D. (AAI '21)

Co-PI: Ivan Vujkovic-Cvijin, Ph.D., assistant professor,
Cedars Sinai Medical Center

Project Title: Influence of commensal microbiota in the maintenance of memory T cells

AWARDS



From left: Mehrad, Wheeler, and Laubenbacher

Borna Mehrad, M.D. (AAI '22)

Professor
University of Florida

Postdoctoral Fellow: Matthew G. Wheeler, Ph.D. (AAI '23)

Co-PI: Reinhard C. Laubenbacher, Ph.D., professor,
University of Florida

Project Title: Modeling the neutrophil response to *Aspergillus*



From left: Sharpe, Markson, and Liu

Arlene H. Sharpe, M.D., Ph.D. (AAI '96)

Chair and Professor
Harvard Medical School

Postdoctoral Fellow: Samuel C. Markson, Ph.D. (AAI '21)

Co-PI: David Liu, M.D., assistant professor,
Dana Farber Cancer Institute

Project Title: Characterizing the roles of PD-1 and
CTLA-4 blockade in combination vs. monotherapy



From left: Sahoo, Sinha, and Ghosh

Debashis Sahoo, Ph.D. (AAI '21)

Associate Professor
University of California, San Diego

Postdoctoral Fellow: Saptarshi Sinha, Ph.D. (AAI '23)

Co-PI: Pradipta Ghosh, M.D., professor,
University of California, San Diego

Project Title: Biology of post-COVID-19 interstitial lung disease



From left: Snyder, Lan, and Robinson


Michael P. Snyder, Ph.D. (AAI '22)

Chair and Professor
Stanford University

**Postdoctoral Fellow: Linda (Yu-Ling) Lan, D.V.M.,
Ph.D. (AAI '20)**

Co-PI: William H. Robinson, M.D., Ph.D. (AAI '14),
professor, Stanford University

Project Title: Using wearables and micro-sampling to
identify biomarkers in post-acute infection syndromes



From left: Seshadri, Cross, and Bradley

Chetan Seshadri, M.D., Ph.D. (AAI '18)

Associate Professor
University of Washington

Postdoctoral Fellow: Deborah L. Cross, Ph.D. (AAI '22)

Co-PI: Philip H. Bradley, Ph.D., professor,
Fred Hutchinson Cancer Center

Project Title: Understanding T-cell targeting of *Mtb* antigens in
hosts with natural resistance to *Mtb* infection and TB progression

Applications for the 2024 AAI Intersect Fellowship Program
are being accepted now through September 6, 2023.
For complete program information, including application
and eligibility requirements, and to view past recipients,
visit www.aai.org/IntersectFellowship.

AAI Outreach Program Update

The AAI Outreach Program provides career development opportunities for young investigators by supporting podium and poster presentation awards at member-organized immunology meetings throughout the United States. The program most recently provided sponsorship at the conferences highlighted in this section.

Midwinter Conference of Immunologists (MCI)

The 61st MCI was held from January 28–31, 2023, at Asilomar Conference Grounds in Pacific Grove, CA. The meeting drew more than 300 attendees from the United States and internationally. This year, the sessions were organized by naming them after songs from the musical *Hamilton*, and each speaker was asked to provide their own walk-up music clip related to their talk title, which the audience thoroughly enjoyed!

The meeting was organized in part by Christel H. Uittenbogaart, M.D. (AAI '84), professor, David Geffen School of Medicine at the University of California, Los Angeles; Amanda Jamieson, Ph.D. (AAI '15), associate professor, Brown University; and Deepta Bhattacharya, Ph.D. (AAI '09), professor, University of Arizona.

AAI supported 10 poster awards and five podium presentation awards at MCI this year. Recipients of the Ray Owen Poster Awards included:

- Kathya Arana, graduate student, University of California, Berkeley
- Katharine Block, Ph.D., postdoctoral fellow, University of Minnesota
- Marlee Busalacchi, graduate student, Grand Valley State University
- Shaina Carroll, graduate student, University of California, Berkeley

- Kim Foster, graduate student, University of Washington
- Sarah Gayer, graduate student, University of California, San Francisco
- Owen Jiang, graduate student, University of California, San Francisco
- Roxroy Morgan, Ph.D. (AAI '22), postdoctoral fellow, University of Chicago
- Miguel Reina-Campos, Ph.D., postdoctoral fellow, University of California, San Diego
- Brenna Remick, graduate student, University of California, Berkeley

Recipients of the Ray Owen Young Investigator Awards were:

- Payton De La Cruz, graduate student, Brown University
- Nicholas Jarjour, Ph.D. (AAI '19), postdoctoral fellow, University of Minnesota
- Lauren Landau, graduate student, Harvard Medical School
- Rina Matsuda, Ph.D., postdoctoral fellow, University of Pennsylvania
- Kelly Otsuka (AAI '21), graduate student, University of Utah



At MCI, recipients of the Ray Owen Poster Awards (pictured in front row from left): Foster, Gayer, and Arana; and pictured in back row from left: Busalacchi, Block, Morgan, Jiang, Carroll, Remick, and Reina-Campos



At MCI, recipients of the Ray Owen Young Investigator Awards (pictured from left): De La Cruz, Landau, Otsuka, Matsuda, and Jarjour

Conference of Research Workers in Animal Diseases (CRWAD) and American Association of Veterinary Immunologists (AAVI) Symposium

The AAVI Symposium drew members of more than 100 research institutions from around the world at the CRWAD. This was a hybrid event held on January 22–24, 2023, at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL. The AAVI Symposium was organized by Jodi McGill, Ph.D. (AAI '15), associate professor, Iowa State University; Crystal L. Loving, Ph.D. (AAI '13), research immunologist, National Animal Disease Center (NADC), Agricultural Research Service (ARS), United States Department of Agriculture (USDA); Carol Chitko-Mckown, Ph.D., research microbiologist, U.S. Meat Animal Research Center, ARS, USDA; Laura C. Miller, Ph.D., research microbiologist, NADC, ARS, USDA; Randy E. Sacco, Ph.D., microbiologist, NADC, ARS, USDA; and Heather L. Wilson, Ph.D., research scientist, Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada.

A total of 27 graduate students participated in podium and poster presentation competitions. Six graduate students selected by AAVI members received AAI Young Investigator Awards. Award recipients were:


- Leonie Bettin, graduate student, Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada
- Lauren Crawford, graduate student, Iowa State University
- Wenliang He, graduate student, Texas A&M
- Camille Holmes, graduate student, Cornell University
- B. Tegner Jacobson, graduate student, Montana State University
- Beulah Samuel, graduate student, Iowa State University



At AAVI, Dr. Amelia Woolums (left), Distinguished Veterinary Immunologist Awardee and keynote speaker, with Laura Miller, president-elect for the AAVI




At AAVI, (pictured from left): AAVI Past President Jodi McGill with awardees Samuel, Jacobson, and Holmes



More Than 100 Years of AAI History

Visit www.aai.org/history for stories of immunology past and present, the Oral History Project, and the AAI Timeline, which chronicles 100-plus years of immunology history—and more.



2023 ADVANCED COURSE IN IMMUNOLOGY

July 23–28, 2023 | The Westin Copley Place | Boston, Massachusetts

Director: Wayne M. Yokoyama, M.D., DFAAI

Washington University School of Medicine

Don't miss the premier course in immunology for research scientists!

This intensive course is directed toward advanced trainees and scientists who wish to expand or update their understanding of the field. World-renowned immunologists will present recent advances in the biology of the immune system and address its role in health and disease.

This is not an introductory course; attendees will need to have a firm understanding of the basic principles of immunology and laboratory techniques.

Faculty

Ulrich H. von Andrian, *Harvard Medical School; Ragon Institute of MGH, MIT, and Harvard*
Anatomy of the Immune Response

Jonathan C. Kagan, *Boston Children's Hospital, Harvard Medical School*
Innate Immunity: Pattern Recognition and Anti-microbial Mechanisms

Susan Carpenter, *University of California, Santa Cruz*
Innate Immunity: Gene Regulation

Wayne M. Yokoyama, *Washington University School of Medicine*
NK Cells—Their Receptors and Function in Health and Disease

Keith B. Elkon, *University of Washington*
Innate Immune Signaling: Nucleic Acid Sensors

Claudia Jakubzick, *Geisel School of Medicine at Dartmouth*
Myeloid Cells in Immune Responses

Stephanie Eisenbarth, *Northwestern University Feinberg School of Medicine*
Dendritic Cells

Eugene M. Oltz, *The Ohio State University, Wexner School of Medicine*
The Generation and Modification of Lymphocyte Antigen Receptor Genes

Michael P. Cancro, *University of Pennsylvania Perelman School of Medicine*
B Cell Development

Avery August, *Cornell University*
T Cell Development

Kai W. Wucherpfennig, *Dana-Farber Cancer Institute, Harvard Medical School*
MHC-restricted Antigen Presentation to T Cells

Lawrence P. Kane, *University of Pittsburgh*
Signaling from Antigen Receptors

Stephen Jameson, *University of Minnesota Medical School*
T Cell Memory

Deepta Bhattacharya, *University of Arizona*
B Cell Memory

Cathryn Nagler, *University of Chicago*
Effect of the Microbiome on Immunity

Sara Cherry, *University of Pennsylvania Perelman School of Medicine*
Immune Response to Viruses

Julie Zikherman, *University of California, San Francisco, School of Medicine*
B Cell Tolerance and Autoimmunity

Mark S. Anderson, *University of California, San Francisco, School of Medicine*
T Cell Tolerance and Autoimmunity

Francisco J. Quintana, *Brigham and Women's Hospital, Harvard Medical School*
Neuroimmunology

Robert D. Schreiber, *Washington University School of Medicine*
Tumor Immunology

Darrell J. Irvine, *Massachusetts Institute of Technology*
Engineering and Modulating the Immune Response

Joanne L. Viney, *Seismic Therapeutics*
Immunotherapeutics

Megan A. Cooper, *Washington University School of Medicine*
Redefining Human Immunology

Galit Alter, *Ragon Institute of MGH, MIT, and Harvard*
Vaccines

For complete course details and registration, visit www.aai.org/AdvancedCourse.

For assistance, contact (301) 634-7178 or meetings@aai.org.

AAI Appoints Gail A. Bishop as Incoming Editor-in-Chief of *The Journal of Immunology*



The AAI Council is pleased to announce the appointment of Gail A. Bishop, Ph.D., DFAAI (AAI '84), as the incoming editor-in-chief of *The Journal of Immunology* (*The JI*). Dr. Bishop is a professor of microbiology and immunology in the Department of Microbiology and Immunology at the University of Iowa Carver College

of Medicine. Dr. Bishop's five-year term will commence on January 1, 2024, and end December 31, 2028.

Bishop received a Ph.D. degree in cellular and molecular biology from the University of Michigan, Ann Arbor, under the mentorship of Drs. Joseph Glorioso and Stanley Schwartz. Her doctoral thesis focused on the immune response to Herpes Simplex virus. She completed postdoctoral work at the University of North Carolina, Chapel Hill, in the laboratories of Drs. Geoffrey Haughton and Jeffrey Frelinger (AAI '76), where she focused on understanding the molecular mechanisms of B lymphocyte activation and the structure-function relationship of B cell signal receptors.

Bishop was appointed assistant professor of microbiology at the University of Iowa in 1989, promoted to associate professor with tenure in 1994, and to professor in 1998. She was appointed as endowed College of Medicine Distinguished Professor of Microbiology in 2001 and Holden Chair of Cancer Biology in 2004. From 1998 to 2013, she served as the director of the Ph.D.-granting Immunology Graduate Program. In 2004, she became associate director for basic science research at the Holden Comprehensive Cancer Center. She currently serves as director of the Center for Immunology and Immune-Based Diseases at the University of Iowa.

The Bishop lab studies the molecular mechanisms that underlie the processes of lymphocyte activation and tolerance. Particular areas of focus are lymphocyte signaling and interactions between innate and adaptive immune receptors.

Bishop has a long history of service to AAI. She has been both an associate and section editor of *The JI*. She served on the AAI Council from 2007 to 2014, including as AAI councilor from 2007 to 2011, AAI vice president from 2011 to 2012, AAI president from 2012 to 2013, and AAI past president from 2013 to 2014. She was named a Distinguished Fellow of the AAI in 2019. Bishop served as the AAI representative to the Council of the International Union of Immunological Societies from 2016 to 2022.

Beyond her involvement with AAI, Bishop has also served on the Cell Biology and Signal Transduction grant review panel of the National Science Foundation; the Microbiology & Immunology review panel of the American Heart Association; and served as a member and Chair of the NIH Tumors, Tolerance, and Transplantation study section. She was named a Fellow of the American Association for the Advancement of Science in 2020 and a 2022 Society for Leukocyte Biology Honorary Life Members inductee.

Bishop takes the reins of *The JI* at a pivotal time in scholarly publishing. She was selected as editor-in-chief for her scientific and editorial experience, her broad and deep connections in the field of immunology, and her demonstrated commitment to an evidence-based approach to decision making.

"AAI is delighted to welcome Gail Bishop as editor-in-chief of *The JI*," said AAI President Mark Davis, Ph.D. "Dr. Bishop's extensive experience in immunology, along with her significant contributions to the association, make her particularly well suited for this position. Under her leadership, *The JI* will continue to attract high-quality manuscripts that advance all areas of experimental immunology, including basic and clinical studies."

"I am honored and excited to be selected as the next editor-in-chief of *The JI*," said Bishop. "I remember well how thrilled I was to have my first *Ji* paper accepted for publication when I was a graduate student. In the many years since, I have watched my students and postdoctoral fellows experience this with their own *Ji* papers. The challenges facing nonprofit scientific society journals today are considerable. However, *The JI* and I, as incoming editor-in-chief, are fortunate to have an exceptionally strong team to face these challenges. Contributors to this team include outstanding AAI staff and leadership, an active and committed AAI Publications Committee and governing Council, and a talented editorial board. I look forward to working with them to pursue initiatives to enhance and increase the success of *The JI* and to ensure that AAI journals thrive as leaders of the immunology community in the future."

Founded in 1916, *The JI* is the most highly cited publication in the field of immunology. Its editors-in-chief of the last 25 years include:

- Frank W. Fitch, M.D., Ph.D. (1997–2003)
- Robert R. Rich, M.D. (2003–2008)
- Jeremy M. Boss, Ph.D. (2008–2013)
- Pamela J. Fink, Ph.D. (2013–2018)
- Eugene M. Oltz, Ph.D. (2018–2023)

Lessons from the Annual Meeting Roundtables

Each year at The American Association of Immunologists (AAI) annual meeting, the Committee on the Status of Women, the Education Committee, and the Minority Affairs Committee offer roundtable sessions that give early career immunologists an opportunity to speak with experienced immunologists and other science professionals about a wide range of career topics—everything from what it is like to work in a particular job setting to how to address challenges in advancing one's career. The advice shared in these mini-mentoring sessions is invaluable. The AAI Newsletter has invited mentors from these sessions to share their knowledge with our readership.

Top Five Questions (and Answers!) about Careers in Science Policy



By Yvette R. Seger, Ph.D., Director of Science Policy, Federation of American Societies for Experimental Biology (FASEB)

During IMMUNOLOGY2022™, I had the pleasure of meeting many early career scientists as a discussion leader during the Careers in Science roundtable

session. Table topics spanned the breadth of opportunities available to Ph.D. scientists, including research careers in academia, industry, and government, as well as careers that support the research enterprise, such as publishing, consulting, and my area of professional expertise—science policy. Here, I summarize the top five recurring questions (and answers) regarding careers in science policy.

What *is* science policy?

To be honest, after nearly 20 years in the field, I still struggle with this question! Like the science it represents, science policy is a broad field that encompasses a range of disciplines, including advocacy, legislative affairs, regulatory process, communications, and diplomacy, to name a few. In short, science policy is the network of stakeholders and activities that oversee the conduct and application of scientific research. This is further categorized as “science for policy”—the use of scientific findings as the basis for public policy—and “policy for science”—the laws, regulations, and policies that affect the conduct of science. For instance, the COVID-19 guidelines issued by the U.S. Centers for Disease Control and Prevention provide recent examples of science for policy, while the National Institutes of Health’s (NIH’s) Data Management and Sharing Policy is an example of policy for science as is the grant peer review process.

Where do science policy professionals work?

A better question might be where *they don't* work, because science policy professionals can be found within all branches of the federal government as well as many state governments; academic institutions; industry; consulting groups; and nonprofit organizations such as scientific societies, patient advocacy groups, and research foundations. While many science policy professionals are based in the Washington, DC, area, policy career opportunities are available across the United States and abroad.

What skills do I need to be successful in science policy?

For many, science policy may seem like an intimidating career path because it flexes different skills than those used by scientists in their day-to-day research activities. However, rest assured that your scientific training provides transferable skills to prepare you for a range of careers beyond benchwork. Such skills include critical thinking, data analysis, and the innate curiosity that allows scientists to master new techniques and topics in a short amount of time. The scientific method hones real-life project management skills, from designing one's own project and coordinating research collaborations to reporting research outcomes in publications and grant reports. These skills are just as essential to a science policy analyst as they are to a principal investigator on an NIH grant!

Skills that might require additional development include communication to non-scientific audiences, consensus building, and networking. Policy communications range from short newsletter articles and analytical reports to organizational statements and testimony. Seek out opportunities to practice communicating in the active voice and challenge yourself to present your science in non-technical terms. Most policy decisions are made based on the input of a wide range of stakeholders. Thus, any activity, such as serving on a planning committee for a department- or organization-wide event will provide experience in delegation and consensus building. Finally, policy work hinges as much

on fostering relationships as it does on subject expertise, so take the opportunity to build and maintain your professional network. This can be done through networking events, informational interviews, and connecting with individuals through social media platforms like LinkedIn and Twitter.

How can graduate students and postdocs get involved in science policy?

Interested in science policy but not sure if it's the career path for you? Fortunately, there are many opportunities for you to engage in science policy as an active researcher. Time commitments for these activities can range from a few hours a month (staying informed of science policy issues in the news or writing about policy topics for a department or institutional newsletter) to more substantial time commitments (organizing a science policy discussion group, serving on policy-oriented committees, or coordinating policy events).

Formal programs such as the *AAI Public Policy Fellows Program* provide the opportunity for early career researchers to learn about and engage in the public policy and legislative activities of society. This year-long program seeks to enhance participants' awareness of the roles played by different branches of the U.S. government in the development of policies affecting biomedical research and teach advocacy

skills that are put to the test during an in-person Capitol Hill Day. The Federation of American Societies for Experimental Biology (FASEB), of which AAI is a member, also offers opportunities for early career researchers to serve on its *Science Policy Committee* and *Board of Directors*.

Do I have to do a science policy fellowship to get a job in science policy?

The short answer is no. Participation in a science policy fellowship is not a prerequisite for success in science policy. However, they are a great way to gain real-world policy experience and build your network. The National Academies' *Christine Mirzayan Science and Technology Policy Fellowship* provides a 12-week experience, while the *AAAS Science and Technology Policy Fellowship* is a one- to two-year opportunity to work within the U.S. legislative and executive branches. Additional organizations and even state governments offer science policy fellowships, a comprehensive list of which is available [here](#).

Connect with the author!

Email: yseger@faseb.org

LinkedIn: <https://www.linkedin.com/in/yvetteersegerphd>

Twitter: [@YvetteSeger](https://twitter.com/YvetteSeger)



NEW FROM AAI

The Journal of Immunology and ImmunoHorizons Special Collections

The *Journal of Immunology* and *ImmunoHorizons* special collections provide authoritative, up-to-date overviews of critical areas in immunology. These reviews and special features focus on rapidly developing topics, such as COVID-19, mpox, and systems immunology, and provide an indication of future directions.

Visit <https://journals.aai.org/collections> today!



SCANDAL! AT THE FDA

WASHINGTON, DC, 1960 — Henry Welch (AAI 1950), the chief of the Division of Antibiotics at the Food and Drug Administration (FDA), has resigned in the face of allegations of corruption. Welch used his position at the FDA to help establish two for-profit journals supported by pharmaceutical advertisements. Although he claimed to receive only “an honorarium” as editor of those journals, it turned out that the honoraria amounted to more than \$250,000 over seven years—about twice his FDA salary. His resignation comes less than a month before his scheduled retirement.



Henry Welch

Welch was one of the first AAI members at the FDA. As director of the Division of Penicillin Control and Immunology, he was responsible for testing every batch of penicillin used by the armed forces in World War II, conducting tests of his own design. After the war, he was appointed director of the Division of Antibiotics, where he had primary responsibility for new drug approval.

FDA FOUNDED TO ENSURE SAFETY

At the turn of the 20th century, there were very few restrictions or standards on producing and selling medicines and drugs. Anyone could sell a “medicine” without disclosing the ingredients, and they could make any claim they wanted regarding its effects. As public awareness of the dangers of this situation was raised by exposés from Upton Sinclair and other journalists, the demand for regulation led to government action.

The proliferation of antitoxins and vaccines in the late 19th century saved many lives, but lax safety standards also caused unnecessary deaths. After a contaminated diphtheria antitoxin killed several St. Louis children in 1901, the Biologics Control Act of 1902 established the first federal biologics regulations, including labeling requirements and unscheduled inspections.

The Pure Food and Drug Act of 1906 outlawed adulteration of drugs and required labeling of active ingredients. This necessitated a robust infrastructure of testing and evaluation. At first, regulatory power was held by the USDA Bureau of Chemistry, but in 1927 the FDA was founded to implement federal standards for food and drugs.

Immunology History Made in the Nation's Capital



The history exhibit at IMMUNOLOGY2023™

WASHINGTON, DC, 2023 — A record-breaking 4,168 immunologists, exhibitors, and other scientists met in DC this year to present their cutting-edge research, network with colleagues, and attend lectures by some of the world's leading scientists. The history of immunology in the area was celebrated in both a history exhibit and the return of the newly updated AAI Timeline.

The American Association of Immunologists got its foothold in DC in 1916, when the AAI Council extended honorary memberships to senior scientists at the Army Medical

School, the Naval Medical School, and the Hygienic Laboratory of the Public Health Service—the precursor of the NIH. Membership in the region grew swiftly thanks to the proliferation of immunological research at government, university, and private institutions.

Today, the greater DC-Maryland-Virginia area has one of the largest concentrations of AAI members in the country, and many more immunologists have temporarily called the region home while they completed governmental fellowships and training.

INSIDE:

TOP SECRET RESEARCH BY
AAI IMMUNOLOGISTS

NATION'S FIRST IMMUNOLOGY
DEPARTMENT FOUNDED

OPPORTUNITIES INCREASE
AT HOWARD UNIVERSITY

A CHARTER MEMBER IN VIRGINIA

BIOLOGICS “LAB TECHNICIAN”
IDENTIFIED AFTER DECADES

PANDEMIC AVERTED

USDA ENABLES FIRST
PIG-TO-HUMAN HEART

Editor:



John Emrich, Ph.D.

Chief Correspondent:

Charles Richter, Ph.D.



TOP SECRET RESEARCH BY AAI IMMUNOLOGISTS




Elvin Kabat (top) and Theodor Rosebury

FREDERICK, MD, 1947 — Elvin A. Kabat (AAI 1943, president 1965–66) and Theodor Rosebury (AAI 1953) have published a lengthy article in *The Journal of Immunology (The II)* warning the nation of the dangers of biological weapons. During World War II, the pair of scientists worked under conditions of extreme secrecy at the U.S. Army base to understand which microorganisms could be used against American forces and how to be ready for them. No classified material was used in the article printed in *The II*.

About 45 miles north of DC, Fort Detrick began as a small airfield in 1931, but became critically important during the war as the center of the U.S. armed forces biological weapons division. Although the U.S. military never used biological weapons, there was a constant fear that the Axis powers might. Later, during the Cold War, these concerns extended to the Soviet Union as well.

In 1969, the bioweapons research program at Fort Detrick became the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). All work done at this facility must remain within the confines set by Richard Nixon's 1969 executive order renouncing "the use of lethal biological agents and weapons, and all other methods of biological warfare."

The research at USAMRIID had renewed urgency during the 2001 anthrax attacks, when packages containing active anthrax spores were sent through the mail to reporters, Senators, and Representatives, resulting in 22 infections and five deaths. Immunologists at Fort Detrick were instrumental in developing guidelines for treatment in the case of anthrax exposure, as well as how to address the potential weaponization of many other pathogens.



An anthrax-containing envelope received at the offices of Senator Tom Daschle

Nation's First Immunology Department Founded



The original Johns Hopkins Hospital

BALTIMORE, MD, 1916 — Johns Hopkins University has become the home to the first immunology department in the United States. William H. Welch established the School of Hygiene and Public Health with a grant from the Rockefeller Foundation and decided to include a separate Department of Immunology. Carrol G. Bull (AAI 1917) joined Welch from the Rockefeller Institute for Medical Research in 1917 and that same year produced the first effective antitoxin for gas gangrene, just in time to save many soldiers from a gruesome death in the trenches of World War I.

OPPORTUNITIES INCREASE AT HOWARD UNIVERSITY




Willie Turner

WASHINGTON, DC, 1977 — Willie Turner (AAI 1973) has come to Howard University from the National Cancer Institute and created the Ph.D. program in microbiology. He established programs in immunology as well as in virology, pathogenic microbiology, cell biology, and parasitology. To staff the new department, Turner recruited 12 minority faculty and required that, upon promotion, they were to take a sabbatical for research. His efforts significantly increased the number of minority scientists in immunology and related fields.

One of the early recruits to the new program was Curla S. Walters (AAI 1973). After receiving her Ph.D. at Georgetown University, Walters taught immunology and microbiology at Howard for 30 years and guided the development of a new integrated medical school curriculum there. In addition to her research and teaching, she coordinated the AAI program for minority high school students as a founding member of the Minority Affairs Committee.

A CHARTER MEMBER OF AAI IN VIRGINIA



Edgar C. L. Miller

RICHMOND, VA, 1913 — Joining the newly formed American Association of Immunologists is Edgar C.L. Miller of the Medical College of Virginia (MCV). Miller, an early researcher of diphtheria antitoxin and serum sickness, has

established the Department of Biochemistry at MCV and pushed for greater funding to develop new treatments for and understanding of diphtheria, tuberculosis, and typhoid fever.


During the influenza pandemic of 1918–19, Miller replaced the director of the emergency hospital in Richmond when he came down with influenza himself. In 1930, Miller became the Directing Librarian of the MCV Library, a position he held for the rest of his career and into retirement as emeritus.

The MCV merged with the Richmond Professional Institute in 1967 to form the Virginia Commonwealth University, which continues to be a major site for immunological research. Longtime VCU immunologist and rheumatologist Shaun Ruddy (AAI 1969) was one of the pioneers of the human complement pathway. With frequent collaborator K. Frank Austen (AAI 1962, president 1977–78), he discovered key components that are now well known to be involved in inflammatory and immune-mediated disorders.



The "Egyptian Building" which originally housed the Medical College of Virginia

Biologics "Lab Technician" Identified After Decades



Hope Hopps, finally identified, pictured with Harry M. Meyer and Paul D. Parkman

BETHESDA, MD, 2018 — This photograph, taken in the 1970s at the Laboratory of Viral Immunology in the NIH Division of Biologics Standards before the unit moved to FDA, was until 2018 captioned "Drs. Harry M. Meyer Jr. (light hair), Paul D. Parkman (dark hair), and a female lab technician...working with rubella antigen in laboratory setting." A researcher at the National Library of Medicine was able to identify the "female lab technician" as Hope E. Hopps (AAI 1958), the research partner of Meyer and Parkman (AAI 1966).



Hope Hopps

More than a lab technician, Hopps was a bacteriologist with a master's degree in microbiology with 89 articles and two patents to her credit, including for the rubella blood test. She developed the BCS-1 cell line essential to ensuring the safety of live poliovirus vaccines. With Parkman and Meyer, Hopps developed the vaccine for rubella, but is rarely credited with the discovery.

Throughout her long career at the FDA, Hopps supported many young scientists and worked as a consultant for the FDA after retirement.

PANDEMIC AVERTED



Maurice Hilleman in his lab at Walter Reed Army Institute of Research

WASHINGTON, DC, 1957 — Maurice R. Hilleman (AAI 1949), chief of the Department of Respiratory Disease at Walter Reed Army Institute of Research, has averted a potential pandemic. In April 1957, Hilleman noticed an article in the *New York Times* about an epidemic of influenza that was spreading through Asia and immediately obtained samples to study. As the discoverer of the “drift and shift” mechanism that produces new strains of virus, he knew that a targeted vaccine had to be produced extremely quickly to avert another influenza pandemic.

Once he identified the strain, Hilleman pressed military and public health leaders to recognize the danger. His campaign led to the production of 40 million doses of a vaccine tailored to the epidemic strain in just a few months. Hilleman would go on to create dozens of vaccines, eight of which are still in current vaccine schedules, and save millions of lives each year.

USDA Enables First Pig-to-Human Heart

BALTIMORE, MD, 2022 — At the University of Maryland School of Medicine, a genetically modified pig’s heart has been successfully transplanted into a human for the first time. This novel operation was made possible in part through the work of immunologist Joan K. Lunney (AAI 1980) and others at the USDA.

Lunney has been working with pigs at the USDA’s Agricultural Research Service (ARS) in Beltsville, MD, since the 1980s and has discovered novel immune mechanisms that help swine resist the common zoonotic foodborne parasites *Trichinella spiralis* and *Toxoplasma gondii*.

Another major project from the Diet, Genomics and Immunology Laboratory at the USDA is the Porcine Translational Research Database, the largest manually curated database for any veterinary species. For 17 years, the database has facilitated the use of pig models for many human diseases as well as elucidating zoonotic transfer of the next potential pandemic viruses.



Joan K. Lunney caring for porcine colleagues

The AAI ASPIRE Award

Encouraging and
supporting early
career investigators



APPLICATION DEADLINE: SEPTEMBER 20

The American Association of Immunologists is pleased to offer a career awards program specifically for early career investigators: The AAI ASPIRE Award.

Purpose

The AAI ASPIRE Award encourages and fosters the development of talented early career AAI member scientists through support to advance their research activities and scientific contributions in immunology—including the opportunity and travel support to disseminate their research in a special symposium at the AAI annual meeting.

The ASPIRE Award annually recognizes up to six outstanding early career investigators for research accomplishments and professional promise in the field.



The American Association of Immunologists annually honors the research achievements and professional promise of over 1,000 scientists through fellowships, career awards, and travel grants. To learn about all AAI awards and grants, visit www.aai.org/Awards.

Eligibility

Principal investigators who are Regular AAI members within 10 years of their advanced degree (Ph.D., M.D., or equivalent) or the end of postgraduate clinical training (whichever date is later at the time of application) are eligible to apply.

Awardee Support

Recipients of the ASPIRE Award will receive:

- a \$2,000 cash award
- complimentary AAI annual meeting registration
- travel support to the AAI annual meeting for presentation of their research in a symposium preceded by the award presentation.

How to Apply

The application cycle is now open. Application materials can be found at www.aai.org/ASPIRE. **Please submit your application by September 20, 2023, at 11:59 p.m. Eastern Time.** AAI encourages applications from women and underrepresented scientists.

For More Information

- For more information, please visit www.aai.org/ASPIRE.
- Direct any inquiries to awards@aai.org.

AAI Grants and Awards

September 6

AAI Fellowship Program for Career Reentry

- **Prize/Award:** In support of immunologists' reentry into the workforce after a qualifying lapse of research or research training, multiple awards providing one year of salary support to postdoctoral trainees who have taken a leave of absence of one year or more for family-related issues, medical absences, or military obligations
- **Eligibility:** Applicants with a tentative written offer of appointment as a postdoctoral fellow in immunology or a related field; trainees funded under this program may not be supported concomitantly by other fellowships that provide salary compensation
- **Details:** www.aai.org/ReentryFellowship
- **Contact:** fellowships@aai.org

September 6

AAI Intersect Fellowship Program for Computational Scientists and Immunologists

- **Prize/Award:** Multiple postdoctoral fellowship awards providing one year of salary support affording immunology researchers the opportunity to train in computational science and/or computational scientists to train in immunology
- **Eligibility:** At least one of the collaborating PIs seeking support must be an AAI member in good standing; application may be for support of a postdoctoral fellow trained in basic bench research to undertake one year of training in computational science, or a postdoctoral fellow trained in computational science to spend one year in an immunology research lab to learn basic immunological principles and laboratory techniques; reciprocal six-month exchanges between labs will also be considered; trainees must be in years 1-5 of postdoctoral training in the physical/mathematical/computational sciences, immunology, or related fields (those who have completed five years of training and transitioned into a second postdoctoral position will be considered on a case-by-case basis); trainees funded under this program may not be supported concomitantly by other fellowships that provide salary compensation
- **Details:** www.aai.org/IntersectFellowship
- **Contact:** fellowships@aai.org

September 20

Nominations open August 1

NEW The AAI Lancefield Mid-Career Achievement Award

- **Prize/Award:** To recognize and further encourage the research and leadership achievements of women in immunology, annually honors one outstanding mid-career investigator for research and leadership within the field; the award recipient will receive a \$5,000 cash award, complimentary AAI annual meeting registration, travel support to present their research in an award lecture during the AAI annual meeting, and an invitation to participate as a table leader during the Careers in Science Roundtables session
- **Eligibility:** Regular AAI members are invited to submit nominations for exceptional AAI regular member investigators who identify as women, are engaged in active research as a principal investigator (or equivalent role), and are within at least seven but no more than 15 years of starting their first independent faculty/scientist position at the time of the award being granted
- **Details:** www.aai.org/Lancefield
- **Contact:** awards@aai.org



2023 AAI Distinguished Service Awardees Clifford Harding and Cherié Butts

September 20

Nominations open August 1

AAI Career Awards

- **Prizes/Awards:** Recognizing investigators over various career stages, multiple awards honoring scientific achievement in immunology (including achievement specifically related to human immunology) and excellence in mentoring the next generation of scientists; included are awards conferring prizes ranging from \$5,000 to \$10,000

The awards are:

- AAI Excellence in Mentoring Award
 - AAI-Steinman Award for Human Immunology Research and Lecture
 - AAI-BioLegend Herzenberg Award and Lecture
 - AAI-Thermo Fisher Meritorious Career Award and Lecture
 - AAI-BD Biosciences Investigator Award and Lecture
 - AAI ASPIRE Awards for Early Career Investigators
 - AAI Lancefield Mid-Career Achievement Award (*new*—see details on page 38)
- **Eligibility:** Any AAI member in good standing nominated by another AAI member in good standing; the AAI ASPIRE Awards accept self-nominations
 - **Details:** www.aai.org/CareerAwards

- **Contact:** awards@aai.org

October 17

Nominations open August 15

AAI Travel for Techniques Awards

Fall application cycle opens August 15

- **Prize/Award:** Multiple awards providing up to \$1,500 each in reimbursement of travel expenses for a visit to another laboratory specifically to learn a technique beneficial to award applicant's research
- **Eligibility:** AAI regular and associate member scientists with independent research programs; awarded travel may be that of the applicant, applicant's trainee, or applicant's lab member (traveler must be an AAI member); award selection is based on relevance of the technique to the applicant's program and financial need
- **Details:** www.aai.org/TravelforTechniques
- **Contact:** awards@aai.org

Non-AAI Grants and Awards

Visit the AAI website at www.aai.org/GrantsAwardsDeadlines for links to non-AAI grant and award program listings and deadlines.

GRIP


Grant Review for Immunologists Program

Get a GRIP: An AAI program designed to help new investigators prepare their NIH grant proposals

The AAI Grant Review for Immunologists Program (GRIP) offers new principal investigators (PIs) access to established PIs for guidance in preparing grant proposals as they embark on their independent careers. Early-career PIs (assistant professors or equivalents) are invited to submit their grants' "Specific Aims" pages to the GRIP coordinator who, with the assistance of a small volunteer subcommittee, will attempt to match each topic of the proposal with the research experience of an established PI. Matches will be made as quickly as possible to allow participants to meet upcoming NIH grant deadlines. Participation is open only to AAI regular members and is strictly voluntary. The program is not intended to supplant internal mentoring programs at applicants' institutions.

To apply, please send your CV and the grant's "Specific Aims" page to infoaai@aai.org. (please write "GRIP" in the subject line)

To volunteer as a mentor, please send your CV and a brief description of your grant-reviewing experience to infoaai@aai.org. (subject line "GRIP")



Program details at aai.org/Education/GRIP



IMMUNOLOGY2024™

THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS



SAVE THE DATE

MAY 3-7, 2024 | CHICAGO, ILLINOIS

[IMMUNOLOGY2024.AAI.ORG](https://immunology2024.aai.org)

Mark Your Calendar for These Important Dates!

Please note that the meetings listed on these pages were still scheduled at press time, but cancellations may occur. Please check an individual meeting's website to confirm that it is still scheduled.

2023

July 12–14

European Mucosal Immunology Group Meeting (EMIG2023)

University of Bern, Bern, Switzerland
<https://emig2023.ch>

August 3–4

Immunology Group of Victoria (IGV) Scientific Meeting 2023

Yarra Valley Lodge Chirnside Park, VIC
www.immunology.org.au/events/IgV-Annual-Scientific-Meeting-2023

August 20–24

International Congress of Neuroimmunology, International Society for Neuroimmunology (ISNI)

Quebec City, Canada
www.isniweb.org/16th-isni-congress-quebec-city-canada

August 28–September 1

International Society for Developmental and Comparative Immunology Congress

Wageningen, The Netherlands
<https://isdci.org/congress>

August 31–September 5

International Complement Workshop 2023

Newcastle, United Kingdom
www.complement.org/ICW-2023

September 2023

International Endotoxin & Innate Immunity Society (IEIIS) 2023 Meeting

Cleveland, OH
<https://ieiis.org/ieiis-2023-meeting>

September 1–5

29th International Complement Workshop 2023

New Castle, United Kingdom
<https://icw2023newcastle.co.uk>

September 5–8

Meeting on Regulating with RNA in Bacteria and Archaea

Hilton Bayfront, St. Petersburg, FL
<https://microbialrnameeting.com>

September 26–29

German Society for Immunology (Dgfi) Joint Meeting with French Society of Immunology (IFC) 2023

Strasbourg, France
<https://dgfi.org/termine>

September 26–29

Society for Natural Immunity (NK2023)

Scandic Holmenkollen Park Hotel, Oslo, Norway
www.nk2023.org

September 27–30

Society for Leukocyte Biology (SLB) 2023

University of Georgia Conference Center, Athens, GA
www.leukocytebiology.org/2023-meeting

September 27–October 1

Society of General Physiologists: Mapping the Pain Landscape—From Molecules to Medicine

Marine Biological Laboratory, Woods Hole, Massachusetts, USA
www.sgpweb.org/sgpfuturemeetings

October 14–17

The Obesity Society: Obesity Week 2023

Dallas, TX
<https://obesityweek.org/attend/future-dates>

October 15–18

International Cytokine & Interferon Society (ICIS) Annual Meeting 2023

Divani Caravel Hotel, Athens, Greece
<https://athens.cytokinesociety.org>

October 16–17

National Academies Workshop: Preparing the Future Workforce in Drug Research & Development

www.nationalacademies.org/event/10-16-2023/preparing-the-future-workforce-in-drug-research-development-a-workshop

October 16–19

25th Annual Upstate New York Immunology Conference (NYIC)

The Otesaga Resort Hotel, Cooperstown, NY
www.amc.edu/NYIC/index.cfm

October 16–20

American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting 2023

San Antonio Marriott Rivercenter, San Antonio, TX
<https://2023.ashi-hla.org/future-meeting-dates>

October 18–22

American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting

Hyatt Regency Chicago, Chicago, IL
www.astmh.org/annual-meeting/past-meetings#Future%20Annual%20Meetings

October 22

International Society for Vaccines (ISV) Annual Congress 2023

Lausanne, Switzerland
<https://isv-online.org>

October 26–28

Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS): The National Diversity in STEP Conference

Portland, OR
www.sacnas.org/conference

October 28–31

American College of Veterinary Pathologists (ACVP) 2023 Annual Meeting

Chicago Marriott Downtown Magnificent Mile, Chicago, IL
www.acvp.org/page/Future_Meetings

November 1–5

American Society of Human Genetics (ASHG) Annual Meeting 2023

Washington, DC
www.ashg.org/meetings/future-past

MEETINGS AND EVENTS

November 1–5

Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023

San Diego Convention Center, San Diego, CA
www.sitcancer.org/education/annualmeeting/archive

November 15–18

ABRCMS 2023: Annual Biomedical Research Conference for Minoritized Scientists

Phoenix, AZ
<https://abrcms.org>

November 17–21

International Veterinary Immunology Symposium (IVIS) 2023

Kruger National Park, South Africa
<http://ivis2023.org>

November 27–December 2

IUIS 2023: 18th International Congress of Immunology

Cape Town, South Africa
<https://iuis2023.org>

December 1–3

World Allergy Congress (WAC) 2023

Bangkok, Thailand
www.worldallergy.org/meetings

December 2–6

American Society for Cell Biology (ASCB): Cell Bio 2023—An ASCB | EMBO Meeting

Boston, MA
www.ascb.org/meetings-events/future-ascb-meetings

December 4–7 | Hybrid Meeting

British Society for Immunology Congress (BSI) 2023

Belfast, Northern Ireland
www.immunology.org/events/british-society-immunology-congress-2023

December 4–8

Australian and New Zealand Society for Immunology (ASI) Annual Scientific Meeting

University of Auckland, Auckland, New Zealand
www.asi2023.org

December 11–15

American Geophysical Union (AGU) Fall Meeting 2023

San Francisco, CA
www.agu.org/Plan-for-a-Meeting/AGUMeetings

2024

January 19–23

Annual Conference of Research Workers in Animal Diseases

Chicago, IL
<https://crwad.org/save-the-date-for-crwad-2023>

Feb 10–14


Biophysical Society (BPS) Annual Meeting 2024

Pennsylvania Convention Center, Philadelphia, PA
www.biophysics.org/upcoming-annual-meetings

April 22–25

Canadian Society for Immunology (CSI) Annual Conference 2024

The Banff Centre, Banff, Alberta, Canada
www.csi-sci.ca/Scientific_Meeting.html



May 8–11

American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Baltimore Convention Center, Baltimore, MD
<https://asgct.org/annual-meeting/future-annual-meetings>

June 1–5

American Transplant Congress (ATC) 2024

Pennsylvania Convention Center, Philadelphia, PA
<https://atcmeeting.org/future-dates>

July 2024

International Congress of Mucosal Immunology (ICMI) 2024

Copenhagen, Denmark
www.socmucimm.org/meetings-events/upcoming-meetings-events

Sept. 1–4

7th European Congress of Immunology (ECI): Conquering Challenges with Immunology

Dublin, Ireland
<https://eci2024.org>

September 2–6

19th European Meeting on Complement in Human Diseases

Lübeck, Germany
www.emchd2024.org

Oct. 20–23

International Cytokine & Interferon Society (ICIS) Annual Meeting 2024

Seoul, Korea
<https://cytokinesociety.org/meetings/future-meetings>

Oct. 21–25

American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting 2024

Marriott Anaheim, Anaheim, CA
<https://2023.ashi-hla.org/future-meeting-dates>

Oct. 23–27

American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting

New Orleans Ernest N. Morial Convention Center, New Orleans, LA
www.astmh.org/annual-meeting/past-meetings#Future%20Annual%20Meetings

Oct. 31–Nov 2

Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS): The National Diversity in STEP Conference

Phoenix, AZ
www.sacnas.org/conference

Nov. 3–6 | Hybrid Meeting

The Obesity Society: Obesity Week 2024

San Antonio, TX
<https://obesityweek.org/attend/future-dates>

Nov. 5–9

American Society of Human Genetics (ASHG) Annual Meeting 2024

Denver, CO
www.ashg.org/meetings/future-past

Nov. 6–10

Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

George R. Brown Convention Center, Houston, TX
www.sitcancer.org/education/annualmeeting/archive

Nov. 16–19

American College of Veterinary Pathologists (ACVP) 2024 Annual Meeting

Hyatt Regency Seattle, Seattle, WA
www.acvp.org/page/Future_Meetings

2025



2026



CONNECT THE DOTS: THINK HUNTER SYNDROME



Silas, age 2

Silas, age 5

A rare combination of common childhood complaints could be an indicator for **Hunter syndrome** (MPS II), a genetic disorder mainly affecting males.¹

If you suspect Hunter syndrome, refer to a geneticist today.



Hearing Loss¹



Otitis Media¹



Sleep Apnea¹




Enlarged Tonsils /Tongue¹

Visit www.hunterpatients.com/healthcare-professionals for more information about Hunter syndrome




1. Wraith JE et al. Genet Med. 2008; 10(7): 508-516



T Cell Therapy Products Demand the GMP Seal

Explore End-to-End GMP Solutions

We are committed to providing high-quality raw materials that play an important, early role in controlling the overall quality, safety, and efficacy of final cell products. From cell activation with recombinant proteins and functional antibodies to optimizing cell expansion with serum-free supplements to preserving cell qualities with ancillary reagents, we provide end-to-end GMP solutions to support the entire workflow – all with the GMP seal.



Serum-free formulations provide superior T cell expansion compared to other media additives.

Learn more at [biolegend.com/en-us/cell-culture/gmp-solutions](https://www.biolegend.com/en-us/cell-culture/gmp-solutions)

World-Class Quality | Superior Customer Support | Outstanding Value

BioLegend products are manufactured in an ISO 13485:2016-certified facility to ensure the highest quality standards. BioLegend is a registered trademark of BioLegend, Inc. All other trademarks are the property of their respective owners.